Use and monitoring of inhalation of nitric oxide using left ventricular assist device

By administering inhaled nitric oxide to LVAD patients and adjusting LVAD parameters, the problem of right ventricular failure after LVAD implantation was solved, which reduced the associated risks and improved the patient's survival rate and quality of life.

CN119075171APending Publication Date: 2024-12-06MALLINCKRODT HOSPITAL PRODUCTS IP LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411277672.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2016-02-12
Filing Date
2017-01-30
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

After implantation of left ventricular assistive device (LVAD), patients often face the problem of right ventricular failure, and the prior art is difficult to effectively reduce related risks and adverse events.

Method used

pulmonary hemodynamic parameters are measured by administering inhaled nitric oxide (NO) to LVAD patients, adjust LVAD parameters, and perform cardiac transplant or drug therapy if necessary to reduce the risk of right ventricular failure and optimize the LVAD settings.

Benefits of technology

It significantly reduces the risk of right ventricular failure during LVAD use, improves the patient's survival rate and quality of life, extends the device's use time, and reduces the occurrence of complications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119075171A_ABST
    Figure CN119075171A_ABST
Patent Text Reader

Abstract

Systems and methods for administering nitric oxide (NO) using a left ventricular assist device (LVAD) are described, as well as systems and methods for monitoring an NO delivery device and / or the LVAD.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This invention application is a divisional application based on a patent application with application date of January 30, 2017, application number 201780018861.4 (international application number PCT / US2017 / 015552), and invention name “Use and monitoring of inhaled nitric oxide while using a left ventricular assist device”.

[0002] CROSS-REFERENCE TO RELATED APPLICATIONS

[0003] This application claims priority to U.S. Patent Application No. 62 / 294,711, filed on February 12, 2016, entitled “Use and Monitoring of Inhaled Nitric Oxide with Left Ventricular Assist Devices,” the contents of which are incorporated herein by reference in their entirety. Technical Field

[0004] Embodiments of the present invention generally relate to the field of methods and devices for delivering and monitoring inhaled nitric oxide (NO). Background Art

[0005] Modern semipermanent continuous-flow left ventricular assist devices (LVADs) are cost-effective and durable surgically implanted mechanical devices that augment or replace the poorly or non-functioning diseased left ventricle of the heart to maintain blood circulation to the body. LVADs are now considered a reasonable alternative to orthotopic heart transplantation, especially given the critical shortage of suitable donor organs. Continuous-flow LVADs have replaced earlier pulsatile models because they are more durable, less bulky, and have been shown to improve survival, exercise capacity, and quality of life. LVADs are used to maintain patients with advanced congestive heart failure (CHF) who cannot respond to medical therapy in order to transition to heart transplantation as destination therapy or to transition to rehabilitation in patients whose CHF is considered at least partially reversible. The frequency of adequate rehabilitation to allow explantation of the LVAD is estimated to be 10-20% in CHF of non-ischemic etiology and <1% in ischemic CHF. In CHF, LVADs are considered adequate when the cardiac index (CI) is <2 L / min / m 2 LVAD implantation is usually indicated when systemic systolic arterial pressure is <90 mm Hg, left atrial pressure is >20 mm Hg, or systemic vascular resistance is >1.57 mm Hg / mL. Advances in durability and miniaturization of LVADs, provided by continuous-flow rather than pulsatile designs, have enabled more widespread and prolonged use.

[0006] Unfortunately, right ventricular failure has been reported in 15% of continuous-flow LVAD recipients and in 20-50% of all LVAD recipients within the first 30 days after implantation. Thus, right ventricular failure remains a major limitation to LVAD use and is associated with significantly worse prognosis.

[0007] Furthermore, continuous-flow LVADs produce reduced peripheral perfusion pulsatility as measured by pulsatility index, pulse pressure, and / or aortic valve opening frequency compared to pulsatile-flow LVAD devices and / or normal circulation from a well-functioning human heart, and this reduced pulsatility has been implicated in a number of adverse events, including reduced peripheral vascular compliance, gastrointestinal bleeding, arteriovenous malformations, hemolysis, pump thrombosis, aortic regurgitation, and reduced rate of left ventricular function recovery.

[0008] Therefore, there is a need for adjunctive therapies that enhance the use of LVADs and / or reduce the risk of LVAD-related right ventricular failure and / or reduce the risk of other LVAD-related adverse events. Summary of the invention

[0009] One or more aspects of the present invention provide novel adjunctive therapies that enhance the effectiveness of LVADs and / or reduce the risk of LVAD-associated right ventricular failure.

[0010] One aspect of the present invention relates to a method for determining whether a patient with pulmonary hypertension will resolve the pulmonary hypertension by continuing to use an LVAD. In various embodiments of this aspect, the method includes measuring one or more pulmonary hemodynamic parameters of a patient with an LVAD to obtain a first pulmonary hemodynamic value; after obtaining the first pulmonary hemodynamic value, administering inhaled NO to the patient with the LVAD; and measuring one or more pulmonary hemodynamic parameters of the patient during or after the administration of inhaled NO to obtain a second pulmonary hemodynamic value. A significant change in a pulmonary hemodynamic parameter from the first pulmonary hemodynamic value to the second pulmonary hemodynamic value can indicate that the patient may resolve the pulmonary hypertension after continuing to use the LVAD. For example, the significant change in the pulmonary hemodynamic parameter can be at least 10 mm Hg mPAP and / or at least 20% PVR, or an equivalent change, as shown by echocardiography, MRI, or other imaging techniques.

[0011] In some embodiments of this aspect, inhaled NO is applied at a concentration of 5 to 80 ppm for at least 10 minutes. Exemplary inhaled NO concentrations include about 5 ppm, about 10 ppm, about 15 ppm, about 20 ppm, about 25 ppm, about 30 ppm, about 35 ppm, about 40 ppm, about 45 ppm, about 50 ppm, about 55 ppm, about 60 ppm, about 65 ppm, about 70 ppm, and about 80 ppm. Exemplary NO application times include about 10 minutes, about 15 minutes, about 20 minutes, about 25 minutes, about 30 minutes, about 35 minutes, about 40 minutes, about 45 minutes, about 50 minutes, about 55 minutes, and about 60 minutes.

[0012] Exemplary pulmonary hemodynamic parameters include mean pulmonary artery pressure (mPAP), diastolic pulmonary artery pressure (dPAP), pulmonary capillary wedge pressure (PCWP), transpulmonary gradient (TPG), and pulmonary vascular resistance (PVR). Other pulmonary hemodynamic parameters include combinations and / or relationships between these parameters, such as the difference between dPAP and PCWP. One or more pulmonary hemodynamic parameters can be measured or estimated by any suitable procedure, such as by performing right heart catheterization, MRI, or echocardiography.

[0013] In one or more embodiments, the method further comprises placing the patient on a heart transplant list if a significant change in a pulmonary hemodynamic parameter occurs from a first pulmonary hemodynamic value to a second pulmonary hemodynamic value, such as a decrease in mPAP of at least 10 mm Hg and / or a decrease in PVR of at least 20%. In some embodiments, the method further comprises removing the LVAD and implanting a donor heart in the patient.

[0014] As an alternative to the above thresholds of 10 mm Hg mPAP and / or 20% PVR, other significant changes in pulmonary hemodynamic parameters may be a decrease of 5 mm Hg (for pressure-related parameters such as mPAP or TPG) or a parameter change of at least 5% (for all parameters). Exemplary significant changes in pulmonary hemodynamic parameters include at least 5 mm Hg, at least 6 mm Hg, at least 7 mm Hg, at least 8 mm Hg, at least 9 mm Hg, at least 10 mm Hg, at least 15 mm Hg, at least 20 mm Hg, or at least 25 mm Hg, and / or a change of at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, or at least 50%.

[0015] Another aspect of the invention relates to a method for optimizing LVAD settings. In various embodiments of this aspect, the method includes administering inhaled NO to a patient with an LVAD; performing an echocardiogram on the patient during administration of the inhaled NO; and adjusting or setting one or more parameters of the LVAD during the echocardiogram and during administration of the inhaled NO. Instead of performing an echocardiogram, other appropriate techniques may be used to set LVAD parameters. In one or more embodiments, adjusting or setting LVAD parameters during administration of NO helps optimize cardiac output.

[0016] In one or more embodiments of this aspect, adjusting or setting one or more parameters of the LVAD includes one or more of: (i) determining a low pump speed setting for the LVAD based on a minimum pump speed required for the patient's aortic valve to open with each heartbeat or (ii) determining a high pump speed setting for the LVAD based on a pump speed at which the patient's heart septum flattens. In some embodiments, increasing aortic valve opening and closing without flattening the septum can include setting a constant speed, or setting a range within which the speed can be adjusted to achieve the above purpose, such as in pulse modulation continuous flow.

[0017] In some embodiments of this aspect, inhaled NO is applied at a concentration of 5 to 80 ppm for at least 10 minutes. Exemplary inhaled NO concentrations include about 5 ppm, about 10 ppm, about 15 ppm, about 20 ppm, about 25 ppm, about 30 ppm, about 35 ppm, about 40 ppm, about 45 ppm, about 50 ppm, about 55 ppm, about 60 ppm, about 65 ppm, about 70 ppm, and about 80 ppm. Exemplary NO application times include about 10 minutes, about 15 minutes, about 20 minutes, about 25 minutes, about 30 minutes, about 35 minutes, about 40 minutes, about 45 minutes, about 50 minutes, about 55 minutes, about 60 minutes, about 1.5 hours, about 2 hours, about 2.5 hours, and about 3 hours.

[0018] In some embodiments, the LVAD setting is changed by a series of incremental adjustments. For example, the LVAD pump speed can be adjusted upward in two or more steps. One or more or all of these steps can be performed during the administration of inhaled NO as described herein.

[0019] Another aspect of the invention relates to a method of reducing the risk of right ventricular failure during LVAD use. In various embodiments of this aspect, the method comprises administering inhaled NO to a patient with an LVAD for at least 12 hours per day for at least 20 days.

[0020] Because patients with LVADs have pre-existing left ventricular dysfunction, it may be important to ensure that the LVAD is functioning properly prior to administering inhaled NO. Thus, in some embodiments, the method further comprises confirming that the LVAD is functioning properly prior to administering inhaled NO.

[0021] In one or more embodiments, inhaled NO is administered after the patient is weaned from cardiopulmonary bypass (CPB).

[0022] Inhaled NO can be administered for days to months or even longer. Exemplary treatment times include 10 days, 15 days, 20 days, 25 days, 30 days, 35 days, 40 days, 45 days, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 1 year, 1.5 years, or 2 years. In some embodiments, inhaled NO is administered to the patient indefinitely.

[0023] In some embodiments of this aspect, inhaled NO is applied at a concentration of 5 to 80 ppm for at least 12 hours per day. Exemplary inhaled NO concentrations include about 5 ppm, about 10 ppm, about 15 ppm, about 20 ppm, about 25 ppm, about 30 ppm, about 35 ppm, about 40 ppm, about 45 ppm, about 50 ppm, about 55 ppm, about 60 ppm, about 65 ppm, about 70 ppm, and about 80 ppm. Exemplary NO application times include about 12 hours per day, about 14 hours per day, about 16 hours per day, about 18 hours per day, about 20 hours per day, about 22 hours per day, or up to 24 hours per day.

[0024] Alternatively, the dosage of NO can be prescribed based on the patient's ideal body weight (IBW). Exemplary NO dosages can range from about 25 to about 150 μg / kg IBW / h, such as about 25, about 30, about 35, about 40, about 45, about 50, about 60, about 70, about 80, about 90, about 100, about 110, about 120, about 130, about 140, or about 150 μg / kg IBW / h.

[0025] In one or more embodiments, the method further includes monitoring one or more output parameters of the LVAD and / or one or more hemodynamic parameters of the patient, comparing one or more output parameters and / or one or more hemodynamic parameters with a predetermined range, and adjusting the dose of inhaled NO if one or more output parameters and / or one or more hemodynamic parameters are outside the predetermined range. In some embodiments, the method further includes providing an alarm if one or more output parameters and / or one or more hemodynamic parameters are outside the predetermined range. These alarms may include audible alarms, visual alarms, somatosensory alarms (e.g., vibrations), and / or text alarms. The inhaled NO dose can be adjusted automatically (e.g., by a NO delivery device or a control system connected to the NO delivery device), or can be manually adjusted by a doctor or other user.

[0026] Examples of LVAD parameters that may be monitored include, but are not limited to, pump speed (eg, rpm), pump flow (eg, L / min), pulsatility index, battery charge, and LVAD status (eg, operational, whether a warning is present).

[0027] Another aspect of the invention relates to a method for monitoring the left ventricle of a patient with an LVAD to determine whether the patient's left ventricle is improving. In various embodiments of this aspect, the method includes reducing the pump rate of the LVAD or shutting down the LVAD; measuring one or more pulmonary hemodynamic parameters of the patient to obtain a first pulmonary hemodynamic value; preloading the left ventricle by administering inhaled NO to the patient; and measuring one or more pulmonary hemodynamic parameters after or during the administration of inhaled NO to obtain a second pulmonary hemodynamic value. In some embodiments, the pulmonary hemodynamic parameter is selected from LAP, PCWP, and CO, or can be any assessment of left ventricular reserve that is used to compensate for increased left ventricular preload that can be measured by right heart catheterization, echocardiography, MRI, or other techniques.

[0028] In some embodiments of this aspect, inhaled NO is applied at least 10 minutes at a concentration of 5 to 80 ppm. Exemplary inhaled NO concentrations include about 5 ppm, about 10 ppm, about 15 ppm, about 20 ppm, about 25 ppm, about 30 ppm, about 35 ppm, about 40 ppm, about 45 ppm, about 50 ppm, about 55 ppm, about 60 ppm, about 65 ppm, about 70 ppm, and about 80 ppm. Exemplary NO application time includes about 10 minutes, about 15 minutes, about 20 minutes, about 25 minutes, about 30 minutes, about 35 minutes, about 40 minutes, about 45 minutes, about 50 minutes, about 55 minutes, about 60 minutes, about 1.5 hours, about 2 hours, about 2.5 hours, about 3 hours, about 3.5 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, or about 8 hours.

[0029] According to one or more embodiments, an increase in LAP and / or PCWP of less than 5 mm Hg from a first pulmonary hemodynamic value to a second pulmonary hemodynamic value indicates that the left ventricle is improving. Other exemplary values ​​indicative of left ventricular improvement include an increase in LAP and / or PCWP of less than 1 mm Hg, 2 mm Hg, 3 mm Hg, 4 mm Hg, 6 mm Hg, 7 mm Hg, 8 mm Hg, 9 mm Hg, 10 mm Hg, 11 mm Hg, 12 mm Hg, 13 mm Hg, 14 mm Hg, or 15 mm Hg. In some embodiments, the method further includes modifying treatment if the left ventricle is improving, such as removing the LVAD from the patient. Other modifications to treatment may include changing supportive medications (e.g., diuretics and / or positive inotropic drugs) given to the patient, such as reducing supportive medications.

[0030] Yet another aspect of the invention relates to a method of exercising the heart of a patient with an LVAD. In various embodiments of this aspect, the method comprises reducing and / or adjusting the pump speed of the LVAD or shutting down the LVAD; preloading the left ventricle by administering inhaled NO to the patient for at least 5 minutes; stopping the inhaled NO administration; and repeating the preloading and stopping to exercise the left ventricle of the patient's heart.

[0031] In some embodiments of this aspect, inhaled NO is applied at least 5 minutes at a concentration of 5 to 80 ppm. Exemplary inhaled NO concentrations include about 5 ppm, about 10 ppm, about 15 ppm, about 20 ppm, about 25 ppm, about 30 ppm, about 35 ppm, about 40 ppm, about 45 ppm, about 50 ppm, about 55 ppm, about 60 ppm, about 65 ppm, about 70 ppm, and about 80 ppm. Exemplary NO application time includes about 5 minutes, about 10 minutes, about 15 minutes, about 20 minutes, about 25 minutes, about 30 minutes, about 35 minutes, about 40 minutes, about 45 minutes, about 50 minutes, about 55 minutes, about 60 minutes, about 1.5 hours, about 2 hours, about 2.5 hours, about 3 hours, about 3.5 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, or about 8 hours.

[0032] Alternatively, the dosage of NO can be prescribed based on the patient's ideal body weight (IBW). Exemplary NO dosages can range from about 25 to about 150 μg / kg IBW / h, such as about 25, about 30, about 35, about 40, about 45, about 50, about 60, about 70, about 80, about 90, about 100, about 110, about 120, about 130, about 140, or about 150 μg / kg IBW / h.

[0033] Preloading of the left ventricle can be performed multiple times per day, such as twice a day, three times a day, four times a day, five times a day, six times a day, seven times a day, eight times a day, nine times a day, or ten times a day. Alternatively, preloading can be performed once a day. If preloading is performed multiple times a day, the preloading procedures can be concentrated together (e.g., separated by a few minutes or hours) or can be dispersed throughout the day. Preloading of the left ventricle can also be performed once a week, two days a week, three days a week, four days a week, five days a week, six days a week, or seven days a week. In an exemplary embodiment, the left ventricle is preloaded several times a day for several days a week, such as two to five times a day for two to four days a week, or other combinations of the above daily and weekly preloading schedules.

[0034] Yet another aspect of the invention relates to methods for reducing the risk of adverse events during LVAD use. In various embodiments of this aspect, the adverse event is associated with reduced pulsatility resulting from LVAD use and / or is associated with NO-mediated impairment of vascular function.

[0035] In various embodiments of this aspect, the method comprises administering inhaled NO to a patient with a continuous flow or semi-pulsatile LVAD for at least 12 hours per day for at least 20 days.

[0036] Because patients with LVADs have pre-existing left ventricular dysfunction, it may be important to ensure that the LVAD is functioning properly prior to administering inhaled NO. Thus, in some embodiments, the method further comprises confirming that the LVAD is functioning properly prior to administering inhaled NO.

[0037] In one or more embodiments, inhaled NO is administered after the patient is weaned from cardiopulmonary bypass (CPB).

[0038] Inhaled NO can be administered for days to months or even longer. Exemplary treatment times include 10 days, 15 days, 20 days, 25 days, 30 days, 35 days, 40 days, 45 days, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 1 year, 1.5 years, or 2 years. In some embodiments, inhaled NO is administered to the patient indefinitely.

[0039] In some embodiments of this aspect, inhaled NO is applied at a concentration of 5 to 80 ppm for at least 12 hours per day. Exemplary inhaled NO concentrations include about 5 ppm, about 10 ppm, about 15 ppm, about 20 ppm, about 25 ppm, about 30 ppm, about 35 ppm, about 40 ppm, about 45 ppm, about 50 ppm, about 55 ppm, about 60 ppm, about 65 ppm, about 70 ppm, and about 80 ppm. Exemplary NO application times include about 12 hours per day, about 14 hours per day, about 16 hours per day, about 18 hours per day, about 20 hours per day, about 22 hours per day, or up to 24 hours per day.

[0040] Alternatively, the dosage of NO can be prescribed based on the patient's ideal body weight (IBW). Exemplary NO dosages can range from about 25 to about 150 μg / kg IBW / h, such as about 25, about 30, about 35, about 40, about 45, about 50, about 60, about 70, about 80, about 90, about 100, about 110, about 120, about 130, about 140, or about 150 μg / kg IBW / h.

[0041] In one or more embodiments, the method further includes monitoring one or more output parameters of the LVAD and / or one or more hemodynamic parameters of the patient, comparing one or more output parameters and / or one or more hemodynamic parameters with a predetermined range, and adjusting the dose of inhaled NO if one or more output parameters and / or one or more hemodynamic parameters are outside the predetermined range. In some embodiments, the method further includes providing an alarm if one or more output parameters and / or one or more hemodynamic parameters are outside the predetermined range. These alarms may include audible alarms, visual alarms, somatosensory alarms (e.g., vibrations), and / or text alarms. The inhaled NO dose can be adjusted automatically (e.g., by a NO delivery device or a control system connected to the NO delivery device), or can be manually adjusted by a doctor or other user.

[0042] Examples of LVAD parameters that may be monitored include, but are not limited to, pump speed (eg, rpm), pump flow (eg, L / min), pulsatility index, battery charge, and LVAD status (eg, operational, whether a warning is present).

[0043] Another aspect relates to a method for optimizing an inhaled NO dose used in conjunction with an LVAD, such as a continuous flow or semi-pulsatile LVAD. In various embodiments of this aspect, the method includes measuring endothelial function in a patient with a continuous flow or semi-pulsatile LVAD, administering inhaled NO to the patient at a first dose, measuring the patient's endothelial function during the administration of inhaled NO, and adjusting the inhaled NO dose to optimize endothelial function. Any appropriate technique can be used to measure endothelial function, including but not limited to flow-mediated dilation (FMD) and / or reactive hyperemia index (RHI). In one or more embodiments, adjusting the NO dose helps to optimize endothelial function and reduce the risk of adverse events associated with NO-mediated impaired vascular function.

[0044] In some embodiments, the method further comprises measuring one or more NO-related molecules and / or other biomarkers of endothelial function in the patient's blood and / or plasma. Exemplary NO-related molecules include whole blood and erythrocyte nitrite (NO2 - ), nitrate (NO3 - ) heme-nitrosylated hemoglobin [Hb(FeII)NO] and cysteine-nitrosylated hemoglobin (also known as S-nitrosohemoglobin SNO-Hb) and nitrosylated plasma proteins. Other biomarkers of endothelial function include, but are not limited to, pulse amplitude tonometry (measurement of post-ischemic swelling of the fingertips) and peripheral artery tonometry (measurement of the size of the brachial artery after release of a blood pressure cuff using ultrasound).

[0045] Another aspect of the present invention relates to a system for coordinating the operation of an LVAD and a NO delivery device. Such a system can be used in any of the indications or methods described herein. In various embodiments of this aspect, the system includes a control system communicated with the NO delivery device and / or the LVAD, wherein the control system monitors one or more parameters of the NO delivery device and / or one or more parameters of the LVAD, and if one or more parameters of the NO delivery device and / or the LVAD are outside a predetermined range, an alarm is provided. The system may also include the NO delivery device and / or the LVAD itself.

[0046] In one or more embodiments, if the NO delivery device fails, the control system reduces the pump speed of the LVAD. The control system can also initiate a weaning procedure for the NO delivery device if the LVAD fails.

[0047] The control system may be integral to the NO delivery device, integral to the LVAD, or a component of a separate control module.

[0048] The present invention also relates to the following specific embodiments:

[0049] 1. A method of determining whether a patient with pulmonary hypertension will resolve the pulmonary hypertension by continued use of a left ventricular assist device (LVAD), the method comprising:

[0050] measuring one or more pulmonary hemodynamic parameters of a patient having an LVAD to obtain a first pulmonary hemodynamic value;

[0051] After obtaining the first pulmonary hemodynamic value, administering inhaled nitric oxide to the patient having the LVAD; and

[0052] measuring one or more pulmonary hemodynamic parameters of the patient during or after the administration of inhaled nitric oxide to obtain a second pulmonary hemodynamic value,

[0053] wherein a reduction of at least 10 mm Hg and / or at least 20% in the pulmonary hemodynamic parameter from the first pulmonary hemodynamic value to the second pulmonary hemodynamic value indicates that the pulmonary hypertension is likely to resolve in the patient upon continued use of the LVAD.

[0054] 2. A method as described in claim 1, wherein the pulmonary hemodynamic parameter is selected from mean pulmonary artery pressure (mPAP), transpulmonary gradient (TPG) and pulmonary vascular resistance (PVR).

[0055] 3. A method as described in claim 1, wherein the inhaled nitric oxide is administered at a concentration of 5 to 80 ppm for at least 10 minutes.

[0056] 4. The method of claim 1 , wherein measuring one or more pulmonary hemodynamic parameters comprises performing right heart catheterization.

[0057] 5. The method according to claim 1, further comprising:

[0058] placing the patient on a cardiac transplant list if the decrease in the pulmonary hemodynamic parameter from the first pulmonary hemodynamic value to the second pulmonary hemodynamic value is at least 10 mm Hg and / or at least 20%; and

[0059] The LVAD is removed and a donor heart is implanted in the patient.

[0060] 6. A method of optimizing settings of a left ventricular assist device (LVAD), the method comprising:

[0061] administering inhaled nitric oxide to patients with LVADs;

[0062] performing an echocardiogram on the patient during administration of inhaled nitric oxide; and

[0063] during the echocardiogram and during the administration of inhaled nitric oxide, adjusting or setting one or more parameters of the LVAD to optimize cardiac output,

[0064] Adjusting or setting one or more parameters of the LVAD includes one or more of: (i) determining a low pump speed setting of the LVAD based on a minimum pump speed required for the patient's aortic valve to open with each heartbeat or (ii) determining a high pump speed setting of the LVAD based on a pump speed at which the patient's heart septum flattens.

[0065] 7. A method as described in claim 6, wherein the inhaled nitric oxide is administered at a concentration of 5 to 80 ppm for at least 10 minutes.

[0066] 8. A method of reducing the risk of right ventricular failure during use of a left ventricular assist device (LVAD), the method comprising:

[0067] confirming that the LVAD is functional prior to administering inhaled nitric oxide;

[0068] Administering inhaled nitric oxide to patients with LVADs for at least 12 hours per day for at least 20 days to reduce the risk of right ventricular failure,

[0069] wherein said inhaled nitric oxide is not initially administered after the patient is weaned from cardiopulmonary bypass (CPB).

[0070] 9. The method of claim 8, wherein the inhaled nitric oxide is administered at a concentration of 5 to 80 ppm or at a dose of 25 to 150 μg / kg IBW / h.

[0071] 10. The method of claim 8, further comprising monitoring one or more output parameters of the LVAD and / or one or more hemodynamic parameters of the patient, comparing the one or more output parameters and / or the one or more hemodynamic parameters with a predetermined range, and adjusting the dose of inhaled nitric oxide if the one or more output parameters and / or the one or more hemodynamic parameters are outside the predetermined range.

[0072] 11. The method of claim 10, further comprising providing an alarm if the one or more output parameters and / or the one or more hemodynamic parameters are outside the predetermined range.

[0073] 12. A method of monitoring the left ventricle of a patient having a left ventricular assist device (LVAD), the method comprising:

[0074] reducing the pump speed of the LVAD or shutting down the LVAD;

[0075] measuring one or more pulmonary hemodynamic parameters of the patient to obtain a first pulmonary hemodynamic value;

[0076] preloading the left ventricle by administering inhaled nitric oxide to the patient; and

[0077] One or more pulmonary hemodynamic parameters of the patient are measured after or during administration of inhaled nitric oxide to obtain a second pulmonary hemodynamic value.

[0078] 13. A method as described in claim 12, wherein the pulmonary hemodynamic parameter is selected from left atrial pressure (LAP), pulmonary capillary wedge pressure (PCWP) and cardiac output (CO).

[0079] 14. The method of claim 12, wherein the inhaled nitric oxide is administered at a concentration of 5 to 80 ppm for at least 10 minutes.

[0080] 15. The method of claim 14, wherein an increase in LAP and / or PCWP from the first pulmonary hemodynamic value to the second pulmonary hemodynamic value of less than 5 mm Hg indicates that the left ventricle is improving.

[0081] 16. The method of claim 15 further comprising modifying treatment if the left ventricle is improving, the modification comprising removing the LVAD from the patient.

[0082] 17. A method as described in claim 15, wherein preloading the left ventricle comprises administering inhaled nitric oxide at a concentration of 5 to 80 ppm for a period of 5 to 30 minutes, and the preloading is performed one to five times per day.

[0083] 18. The method of claim 15, further comprising exercising the heart, the exercising comprising:

[0084] ceasing said inhaled nitric oxide administration; and

[0085] The preloading and stopping are repeated to exercise the left ventricle of the patient's heart. BRIEF DESCRIPTION OF THE DRAWINGS

[0086] Thus, the manner in which the above-described features of the invention can be understood in detail, i.e., a more particular description of the invention briefly summarized above, can be obtained by reference to embodiments, some of which are illustrated in the accompanying drawings. It should be noted, however, that the drawings illustrate only typical embodiments of the invention and are therefore not to be considered limiting of the scope of the invention, as the invention may admit to other equally effective embodiments.

[0087] Figure 1 An exemplary NO delivery device that can be used according to one or more embodiments of the present invention is shown.

[0088] Figure 2 An exemplary NO delivery device that may be used according to one or more embodiments of the present invention is shown;

[0089] Figure 3 An exemplary NO delivery device in communication with a LVAD that can be used according to one or more embodiments of the present invention is shown;

[0090] Figure 4 shows an exemplary hardware configuration that may be used in accordance with one or more embodiments of the present invention;

[0091] Figure 5 shows exemplary input and output parameters that may be used according to one or more embodiments of the present invention;

[0092] Figure 6 shows an exemplary main menu with mode selections that may be used in accordance with one or more embodiments of the present invention;

[0093] Figure 7 shows an exemplary main menu with alarm settings that may be used according to one or more embodiments of the present invention;

[0094] Figure 8 shows an exemplary main menu with configuration settings that may be used in accordance with one or more embodiments of the present invention;

[0095] Fig. 9 An exemplary submenu for assessing the likelihood of resolution of pulmonary hypertension that may be used in accordance with one or more embodiments of the present invention is shown.

[0096] Fig.10 shows an exemplary submenu for optimizing LVAD settings that may be used according to one or more embodiments of the present invention;

[0097] Fig.11 shows an exemplary submenu for reducing the risk of right ventricular failure that may be used in accordance with one or more embodiments of the present invention;

[0098] Fig.12 shows an exemplary submenu for assessing left ventricular function that may be used in accordance with one or more embodiments of the present invention;

[0099] Fig.13 shows an exemplary submenu for cardio exercises that may be used in accordance with one or more embodiments of the present invention; and

[0100] Fig.14An exemplary submenu for controlling clinician settings of a system that may be used in accordance with one or more embodiments of the present invention is shown. DETAILED DESCRIPTION

[0101] Nitric oxide for inhalation

[0102] For inhalation (Nitric Oxide) is an approved drug. Approved by FDA in 2013 The prescribing information for is attached as Appendix 1, thus forming part of the present disclosure, and the entire contents of which are incorporated herein by reference. is a selective pulmonary vasodilator indicated for the treatment of term and near-term (>34 weeks' gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, in combination with ventilatory support or other appropriate medications, to improve oxygenation and reduce the need for extracorporeal membrane oxygenation. The recommended dose is 20 ppm for a maximum of 14 days or until the potential oxygen desaturation resolves. Withdrawal should be gradual. Adverse reactions according to the label include methemoglobinemia and nitrogen dioxide levels, both of which may be dose-dependent.

[0103] Inhaled NO can be delivered via a NO delivery device such as INOmax DS or The invention relates to a novel NO delivery device for use with a ventilator or respiratory gas administration system, each of which delivers an operator-determined concentration of NO diluted with oxygen or an oxygen / air mixture. Other NO delivery devices and features of NO delivery devices are described below, including NO delivery devices having novel features not present in currently available NO delivery devices.

[0104] The NO source used in any of the methods and devices disclosed in the present invention can be a cylinder of compressed gas containing NO, which is typically a mixture with an inert gas such as nitrogen or helium. A NO-containing gas can be produced by manufacturing the gases separately, mixing them in appropriate proportions, and introducing them into suitable cylinders under pressure. The mixing can be carried out in two steps: first, a large amount of NO is diluted with nitrogen in an intermediate cylinder to a concentration of, for example, 5,000 ppm or 28,600 ppm, and then the mixture is further diluted by introducing the mixture into the final cylinder and filling it with more nitrogen, producing a concentration of, for example, 100 ppm or 800 ppm in the final cylinder. Be careful not to introduce any water or oxygen into the cylinder. The cylinder can be equipped with appropriate valves, transported to the point of use, and connected to a NO delivery device to facilitate the patient to inhale the gas.

[0105] Alternatively, the NO source can be a device that produces NO from a suitable nitrogen source, such as air (see U.S. Pat. No. 5,396,882 as a reference, which is incorporated herein by reference) or nitrogen dioxide (see U.S. Pat. No. 7,560,076 as a reference, which is incorporated herein by reference). The nitrogen dioxide source can be, for example, a compressed nitrogen dioxide gas cylinder or a container of N2O4 (which will release nitrogen dioxide when treated under appropriate conditions). The manufacture of the nitrogen dioxide source may include the steps of compressing the nitrogen dioxide gas into a suitable container or introducing N2O4 in liquid form into a suitable container. The container can be supplied in the form of a device including a filter, the filter containing a reducing agent or an antioxidant, such as ascorbic acid, which reduces nitrogen dioxide to form NO at the patient's bedside. When administered, such a NO generating device is typically connected to a gas delivery device (e.g., a ventilator) to facilitate the patient to inhale the newly formed NO gas.

[0106] definition

[0107] As used herein, the term "pulmonary hemodynamic parameter" refers to any parameter used to describe or assess blood flow through the heart and pulmonary vascular system. Examples of pulmonary hemodynamic parameters include, but are not limited to, mean pulmonary artery pressure (mPAP), diastolic pulmonary artery pressure (dPAP) [also known as pulmonary artery diastolic pressure (PADP)], systolic pulmonary artery pressure (sPAP) [also known as pulmonary artery systolic pressure (PASP)], pulmonary capillary wedge pressure (PCWP) [also known as pulmonary artery wedge pressure (PAWP)], left atrial pressure (LAP), transpulmonary gradient (TPG), pulmonary vascular resistance (PVR) and cardiac output (CO).

[0108] Many of the above pulmonary hemodynamic parameters are interrelated. For example, PCWP is often used as a more convenient, less invasive rough estimate of LAP. As another example, PVR is related to mPAP, PCWP, and CO according to the following equation:

[0109] PVR∝(mPAP–PCWP) / CO

[0110] As another example, TPG is the difference between mPAP and PCWP, as shown in the following equation:

[0111] TPG=mPAP-PCWP

[0112] As another example, mPAP is related to dPAP and sPAP according to the following equation:

[0113] mPAP=(2 / 3)dPAP+(1 / 3)sPAP

[0114] In some embodiments, pulmonary hemodynamic parameters are measured directly, for example during right heart catheterization. In other embodiments, pulmonary hemodynamic parameters are estimated and / or assessed by other techniques such as magnetic resonance imaging (MRI) or echocardiography.

[0115] The phrase "resolution of pulmonary hypertension (PH)" or variations thereof refers to a reduction in PH below a clinically relevant threshold. An example of resolution of PH is when a patient's mPAP decreases below a threshold of 25 mmHg. However, in patients with severe right ventricular failure, the ventricle may be so weak that it cannot generate enough force to raise the sPAP so that the mPAP is at least 25 mmHg. In these patients, PH and its resolution can be assessed by analyzing the difference between dPAP and PCWP.

[0116] Right ventricular failure in LVAD patients

[0117] As mentioned above, right ventricular failure is a common problem after LVAD implantation. Right-sided heart failure after LVAD is primarily related to the dynamic effects of the LVAD itself and / or underlying right ventricular disease, as postoperative right heart failure occurs in only a small percentage of orthotopic heart transplants performed in a similar population.

[0118] Post-LVAD right ventricular failure can be defined pathophysiologically as the inability of the right ventricle to maintain adequate unloading of the LVAD-assisted left ventricle despite adequate right ventricular preload or as the ability to maintain adequate unloading of the LVAD-assisted left ventricle only at the expense of significantly elevated central venous pressure. Post-LVAD right heart failure is often operationally defined as the need for implantation of a right ventricular assist device (RVAD), the need to re-establish inhaled NO for more than 48 hours, or the need for inotropic therapy for more than 14 days. Recent retrospective studies have implicated a variety of different preimplantation clinical and hemodynamic parameters as predictive of post-LVAD right heart failure, with little consensus on the most informative or predictive factors; thus, a full understanding and accurate prediction of post-implant right heart failure remains a clinical and mechanistic issue. Putative predictors include nonspecific demographic, clinical, and laboratory measures of overall disease burden or patient “frailty,” as well as conventional hemodynamic and echocardiographic measures of left ventricular, right ventricular, and pulmonary vascular status, and very specific and specialized functional imaging parameters of the right ventricle. The pathophysiology of right ventricular failure after LVAD implantation appears to be multifactorial and includes preoperative right ventricular dysfunction and pulmonary hypertension (PH), right ventricular ischemia, perioperative fluctuations in pulmonary vascular resistance (PVR) in the setting of cardiopulmonary bypass (CPB), excessive right ventricular preload, and altered interventricular balance, although the relative importance of each of these factors is highly controversial. Superimposed perioperative procedures and / or their complications, such as intraoperative mechanical and / or ischemic injury to the right ventricle, and intraoperative bleeding requiring massive fluid, colloid, or blood product resuscitation, have been proposed to be acute predisposing or exacerbating factors for perioperative right heart failure associated with LVAD implantation. Importantly, despite optimized LVAD adjustment and medical support, direct and indirect effects of the LVAD itself on the anatomy and function of the left ventricle are also thought to cause or contribute to post-implantation right ventricular dysfunction and right heart failure.

[0119] Interaction between the left and right ventricles in congestive heart failure

[0120] In a healthy heart, it is estimated that the left ventricle contributes 80% of the systolic flow and up to two-thirds of the systolic pressure generated by the right ventricle through a process known as mechanical contractile ventricular interaction (SVI). The (patho)physiological interactions between the left and right ventricles in CHF are very complex. In CHF, the right ventricle may be directly damaged by an underlying disease process affecting the left ventricle. Most commonly, right ventricular failure in CHF results from chronic pulmonary vascular congestion caused by primary left ventricular dysfunction and increased right ventricular afterload caused by PH. In addition, dilation of the left ventricle in CHF realigns the anatomy of the septal musculature to a less efficient lateral orientation, further impairing SVI and therefore overall right ventricular contractility. When combined with increased RV afterload, dysfunctional SVI unleashes a vicious cycle of progressive RV dysfunction and RV failure, and conversely, as the failing RV dilates, it intrudes upon and interferes with the relaxed (diastolic) filling of the LV (termed diastolic ventricular interaction [DVI]), further exacerbating pulmonary vascular congestion and PH, creating an additional vicious cycle of superimposed progressive LV and RV failure. An additional form of distal interventricular interaction occurs at the level of the peripheral circulation, where increased central systemic blood volume and central venous pressure in CHF increase RV preload and RV filling, further increasing septal intrusion into the LV, further worsening DVI. Finally, further interventricular interactions occur at the level of the pulmonary circulation, where chronic elevations in pulmonary venous and capillary pressures induce pulmonary vascular remodeling, producing over time a relatively fixed, structure-mediated increase in PVR that further worsens PH and RV afterload (defined as World Health Organization [WHO] group 2 pulmonary hypertension secondary to left-sided heart disease).

[0121] WHO Group 2 PH secondary to left-sided heart disease

[0122] Up to three-quarters of patients with end-stage CHF exhibit some degree of PH and right ventricular dysfunction, and one-third to one-half of patients have moderate to severe or “fixed” PH that is unresponsive to vasodilator or inotrophic challenge. Pharmacological challenge typically includes some combination of inotropes (dobutamine, dopamine, milnirone), nonspecific vasodilators (nitroglycerin, sodium nitroprusside [SNP]), and / or partially or fully selective pulmonary vasodilators (prostacyclin, prostacyclin analogs, prostaglandin E1, sildenafil, inhaled NO) administered before or after LVAD implantation or orthotopic heart transplantation. The chronically failing left ventricle increases left atrial and pulmonary venous pressures, which increases pulmonary artery pressure (PAP) and right ventricular afterload. With chronic stress, pulmonary vascular remodeling results in increased PVR, which further increases PAP out of proportion to the increase in pulmonary venous pressure, resulting in an increased transpulmonary pressure gradient (TPG) in approximately one-third or more of patients with advanced CHF. However, the extent to which this increased PVR and TPG is mediated by intense (and therefore acutely reversible) compensatory pulmonary vasoconstriction rather than by relatively fixed structural vascular remodeling, and the extent to which each of these components is ultimately reversible in advanced CHF, is often difficult to predict based on previously known methods. As a key mediator between right ventricular output and left ventricular preload, the dynamic state of the pulmonary vasculature in patients with chronic CHF before, during, and after LVAD placement is highly complex and critical to clinical outcome. PH that is unresponsive to medical therapy is associated with an increased risk of right heart failure and an overall poor prognosis after orthotopic heart transplantation and is considered a contraindication to the procedure. In contrast, the predictive ability of preoperative hemodynamic properties of PH for the development of post-LVAD right heart failure is mixed. Indeed, both low pre-implantation PAP (which may indicate poor right ventricular contractility) and high pre-implantation PVR have been reported to predict the subsequent development of right heart failure after LVAD. The presence of fixed PH in end-stage CHF is now considered an indication for LVAD therapy rather than a contraindication to heart transplantation, based in part on the consistent observation that in CHF patients whose “fixed” Group 2 PH is unresponsive to medical intervention before LVAD implantation, chronic unloading of the left ventricle by a well-functioning LVAD reverses PH over time, thereby making these patients eligible for heart transplantation. The greatest improvement in PH status appears to be achieved within the first 6 months of LVAD support and remains stable thereafter. Thus, while the LVAD-treated end-stage CHF population may be preferentially focused on patients with WHO Group 2 PH who are ready for transition to transplantation, destination therapy, or even transition to rehabilitation, the importance of avoiding LVAD-related adverse events, which are associated with worse outcomes after heart transplantation, has recently been emphasized.

[0123] Interventricular interactions and right heart failure after LVAD implantation

[0124] While the beneficial effects of continuous-flow LVADs on survival and quality of life and WHO Group 2 PH are well documented, the direct and indirect effects of these devices on right ventricular function have only recently been evaluated in detail. The same SVI and DVI that play a role in non-LVAD-supported CHF may also play an important clinical and therapeutic role in post-LVAD right heart failure. The implanted LVAD actively increases left ventricular outflow, unloading the left ventricle, thereby reducing pulmonary vascular congestion and lowering right ventricular afterload; however, the same enhanced LVAD outflow increases right ventricular preload, which may overwhelm the functional capacity of a previously stressed and / or compromised right ventricle. Unloading of the left ventricle also resets the SVI and DVI. Current postoperative hemodynamic LVAD management is primarily directed toward restoring normal systemic peripheral end-organ (e.g., kidney and liver) perfusion (measured by CI) to allow for gradual weaning of inotropes and diuretics. Fluid therapy is typically targeted to maintain an initial pump rate >2 L / min and right atrial filling pressure <20 mm Hg. Following discharge, the characteristics of pulmonary vascular congestion and PH, as well as the need for inotropic support, generally decline as measures of peripheral end-organ perfusion progressively improve over days to weeks. Despite the initial reduction in pulmonary vascular congestion, PH, and excessive right ventricular afterload (which together improve right ventricular function), right ventricular dysfunction assessed by transthoracic echocardiography may remain impaired for up to 3 months after successful LVAD implantation (although more rapid improvement has been reported in stable LVAD patients who do not require inotropic support). A still-weak right ventricle may be unable to adapt to the increased forward flow generated by LVAD-assisted left ventricular output, creating a continued risk of right heart failure. The associated increase in right arterial pressure 1 month after LVAD implantation is associated with impaired exercise tolerance, as reliably assessed by the 6-minute walk distance (6MWD), and predicts an increased risk of mortality. Persistent post-LVAD RV dysfunction may reflect a reduced intrinsic capacity of the RV to repair itself and / or therapeutic hemodynamic adjustments that prioritize systemic circulation, exposing the still-weak RV to nonoptimal hemodynamic stress.

[0125] Postoperative Management and Adjustment of LVAD

[0126] Both the native right ventricle and the implanted LVAD are preload-dependent and afterload-sensitive, and adequate but not excessive right ventricular preload is important to maintain adequate left ventricular / LVAD filling without excessive right ventricular volume overload in the immediate postoperative period. LVAD flow must be kept low enough to avoid right ventricular volume overload but high enough to maintain adequate end-organ perfusion. Inotropes such as milrinone, dobutamine, and epinephrine used to wean CPB are typically continued for several days after implantation. Nitroglycerin, SNP, nesiritide, and sildenafil have been used to reduce. Inhaled NO and prostacyclin have also been used to reduce PVR in order to achieve the above without compromising systemic perfusion. However, depending on the setting of the continuous flow LVAD rotation speed, the right ventricular outflow through the pulmonary circulation may be insufficient to reliably fill the left ventricle, resulting in negative pressure in the left ventricle. This negative left ventricular pressure not only affects LVAD function, but also pulls the ventricular septum to the left, disrupting the SVI and essentially eliminating any contribution of the septum to right heart contractility, further reducing right ventricular outflow. This situation can lead to severe right ventricular dysfunction and overt clinical right ventricular failure, which may reduce LVAD preload, further impair its function, and thus worsen heart failure. In the intraoperative setting during LVAD implantation, transesophageal echocardiography (TEE) continuously monitors the position of the ventricular septum during LVAD adjustment and CPB weaning; this is particularly important to monitor and control the acute effects of CPB weaning on the dynamic state of the pulmonary vasculature, which may produce severe acute intraoperative or perioperative PH. Subacute postoperative right ventricular failure secondary to septal deviation and dysfunction is suspected when transthoracic echocardiography (TTE) shows right ventricular dilation with left ventricular narrowing and an aortic valve that remains closed due to negative left ventricular pressure. During the postoperative hospital stay of an average of 6 ICU and 20 hospital days, regular TTE assessment of septal deviation predicts RV failure and guides LVAD speed adjustment to minimize leftward septal deviation and the attendant risk of RV dysfunction and RV failure. For example, a “ramp speed study” under TTE monitoring can be used to adjust the optimal pump rate, taking into account changes in ventricular dimensions, displacement of the atrial and ventricular septa, the frequency of aortic valve opening, and evidence of inadequate LV preload and RV dysfunction. Such TTE-guided optimization is particularly important in patients with a poor 6MWD. Reducing LVAD speed to optimize RV function and / or control of post-LVAD RV failure may require the temporary reintroduction of inotropic support and / or intravenous vasodilators to maintain adequate systemic end-organ perfusion. Despite these intensive measures, RV failure remains the leading cause of early mortality after implantation of even the most modern continuous-flow LVADs.Furthermore, current approaches to optimize LVAD, right arterial, and right ventricular hemodynamics using inotropic support and / or conventional intravenous vasodilators are limited by the fact that these agents may induce arrhythmias and / or systemic hypotension, increase oxygen demand, and worsen oxygenation due to pulmonary ventilation-perfusion mismatch, leaving ample room for new approaches to optimize LVAD function and reduce the risk of right ventricular failure while avoiding these serious pharmacological side effects. Furthermore, other therapeutic approaches may be needed to enable right ventricular outflow through the pulmonary circulation to maintain adequate left ventricular preload in order to adequately fill the LVAD-assisted left ventricle at LVAD settings sufficient to maintain adequate end-organ perfusion during the critical period after implantation.

[0127] Pulmonary vasodilators in the management of patients with left ventricular assist devices

[0128] Through right heart catheterization, the acute pulmonary vasoreactivity test (AVT) using selective pulmonary vasodilators such as inhaled NO is usually performed in other forms of PH, such as pulmonary hypertension (PAH, or WHO Group 1 pulmonary hypertension). AVT using inhaled NO is only performed infrequently and cautiously in non-LVAD-supported CHF patients before heart transplantation, because the acute high selective reduction of PVR and right ventricular afterload may overload the failing left ventricle, thereby increasing right arterial and pulmonary venous pressures, possibly leading to acute pulmonary edema. In contrast, "fixed" and "reversible" PH in late CHF are usually inquired by whether there is a hemodynamic response to the combination of systemically administered non-pulmonary specific vasodilators such as SNP, nitroglycerin or adenosine and acute administration or in some studies for more than 72 hours of positive inotropic drugs. Sometimes, acute or longer infusions of prostacyclin and prostaglandin E1 with the highest tolerated dose (i.e., without systemic hypotension or other systemic side effects) of inotropic drugs or nonspecific vasodilators are used for PH reversibility in this case. Despite significant reductions in systemic vascular resistance (SVR) and the clear evidence that long-term intravenous prostacyclin therapy increases mortality in patients with end-stage CHF, inhaled or intravenous prostanoids are currently considered superior to inhaled NO in patients with CHF not supported by an LVAD in some but not all settings.

[0129] Since early extubation, removal of monitoring lines, and ambulation are recommended, TTE becomes the primary tool to assist in adjusting LVAD settings and hemodynamic fluid and drug therapy in the acute postimplantation setting. Management is complicated by the fact that the right ventricle and the pulmonary and systemic circulation simultaneously undergo complex dynamic interactions and adaptations to the newly functioning LVAD, and most vasoactive drugs affect both circulatory systems simultaneously, such as SNP, which dilates both systemic and pulmonary resistance vessels. The high pulmonary selectivity and very short half-life of inhaled NO are ideal attributes for classifying, managing, and optimizing the pulmonary vascular status of patients with CHF who are dependent on LVAD support, and for optimizing LVAD performance in this setting. In the postoperative period, once the acute effects of CPB-induced PH have abated and the patient is hemodynamically stable, AVT with inhaled NO under echocardiographic and / or right heart catheterization guidance can be used to determine whether inhaled NO should be continued to adjust left ventricular preload to optimize SVI and LVAD performance and reduce the risk of acute right ventricular dysfunction and right ventricular failure in the perioperative and postoperative period. Specifically, the dose of inhaled NO will be titrated to right ventricular performance, including measures of SVI and LVAD speed, power, and flow, until the correct combination of normalized / optimized right ventricular function, SVI, cardiac output, pulsatility, and other hemodynamic parameters is achieved. In those patients in whom CI or LVAD or right ventricular performance appears to benefit, inhaled NO will continue during the tapering of inotropes and / or intravenous systemic vasodilators. These parameters will then be re-monitored with echocardiographic assessment to maintain optimal settings during post-acute recovery. It is anticipated that providing critical right ventricular afterload reduction and left ventricular preload enhancement during this period will allow for increased CI with the use of lower LVAD power, improve pulsatility index, improve peripheral perfusion and exercise tolerance, and accelerate and improve early cardiac rehabilitation, as well as reduce the risk of right heart failure. Furthermore, the acute post-response to inhaled NO is highly predictive of the likelihood of subsequent maximal resolution of residual PH due to chronic CHF within 6 months, particularly in those patients whose PH was termed “fixed” preoperatively due to lack of response to a combination of inotropes and systemic vasodilators, as the effectiveness of these medications is often tolerability-limited. Thus, inhaled NO may represent a new paradigm for the optimal management of patients with a functioning LVAD in the days, weeks, and months following implantation.

[0130] New indication for use of inhaled NO with LVAD

[0131] In view of the foregoing, aspects of the present invention provide for the use of inhaled NO as an adjunctive therapy following LVAD implantation. Inhaled NO therapy may be initiated preoperatively prior to implantation or intraoperatively prior to, during, or directly after implantation; such inhaled NO therapy may be continued for a period of time beyond that clinically necessary in order to successfully counteract acute and transient PH that occurs as a direct consequence of the CPB procedure itself. Alternatively, inhaled NO may be initiated (or restarted) following successful withdrawal of CPB and its direct consequences.

[0132] Thus, in various aspects of the invention, inhaled NO will be used in one or more novel applications to predict and prevent the development of right ventricular failure in LVAD recipients following successful weaning from CPB. As described above, right ventricular failure following LVAD support may be the result of: development or persistence of PH; further impairment of right ventricular contractility secondary to changes in SVI and DVI or other ventricular interactions between the RV and the "unloaded" left ventricle; or further intrinsic impairment of right ventricular contractility given the known susceptibility of the right ventricle to impairment of myocardial protection during CPB. The distinction between these contributing causes is important because they are managed differently.

[0133] One aspect of the invention provides a method for predicting that a post-implantation LVAD patient with PH is likely to resolve their PH by sustained LV unloading with a functional LVAD. Patients who demonstrate a significant, dramatic reduction in TPG and / or mPAP and / or PVR and / or other metrics, such as the difference between dPAP and PCWP, using inhaled NO will be more likely to resolve their increased TPG and / or mPAP and / or PVR after LVAD therapy, such as after several months of LVAD therapy.

[0134] When an acute vasoreactivity test (AVT) is performed prior to LVAD implantation, PAP is a combination of increased pulmonary vascular resistance and elevated post-capillary pressure, measured as PCWP or right arterial pressure (RAP). Once the LVAD is in place, the PCWP and RAP effects are eliminated, making the AVT results more clearly correlated with pulmonary vascular resistance without the confounding of increased PCWP and RAP. Thus, this aspect of the invention provides an enhanced predictive tool by performing an AVT after LVAD implantation.

[0135] In various embodiments of this aspect, the method includes measuring one or more pulmonary hemodynamic parameters of a patient with an LVAD to obtain a first pulmonary hemodynamic value; after obtaining the first pulmonary hemodynamic value, administering inhaled NO to the patient with the LVAD; and measuring one or more pulmonary hemodynamic parameters of the patient during or after the administration of inhaled NO to obtain a second pulmonary hemodynamic value. A significant improvement in a pulmonary hemodynamic parameter from the first pulmonary hemodynamic value to the second pulmonary hemodynamic value, such as a decrease of at least 10 mm Hg and / or at least 20%, may indicate that the patient is likely to resolve pulmonary hypertension after continued use of the LVAD.

[0136] In some embodiments of this aspect, inhaled NO is applied at a concentration of 5 to 80 ppm for at least 10 minutes. Exemplary inhaled NO concentrations include about 5 ppm, about 10 ppm, about 15 ppm, about 20 ppm, about 25 ppm, about 30 ppm, about 35 ppm, about 40 ppm, about 45 ppm, about 50 ppm, about 55 ppm, about 60 ppm, about 65 ppm, about 70 ppm, and about 80 ppm. Exemplary NO administration times include about 10 minutes, about 15 minutes, about 20 minutes, about 25 minutes, about 30 minutes, about 35 minutes, about 40 minutes, about 45 minutes, about 50 minutes, about 55 minutes, and about 60 minutes.

[0137] Exemplary pulmonary hemodynamic parameters include mean pulmonary artery pressure (mPAP), transpulmonary gradient (TPG), and pulmonary vascular resistance (PVR).One or more pulmonary hemodynamic parameters may be measured by any suitable procedure, such as by performing right heart catheterization.

[0138] Other known methods of performing acute vasoreactivity testing (AVT) with inhaled NO may also be used in addition to or as an alternative to the methods described above with respect to this aspect of the invention, provided that such AVT is performed after LVAD implantation.

[0139] In one or more embodiments of this aspect, the method further comprises placing the patient on a heart transplant list if the decrease in the pulmonary hemodynamic parameter from the first pulmonary hemodynamic value to the second pulmonary hemodynamic value is at least 10 mm Hg and / or at least 20%. In some embodiments, the method further comprises removing the LVAD and implanting a donor heart in the patient.

[0140] As an alternative to the above thresholds of 10 mm Hg and / or 20%, other significant reductions in pulmonary hemodynamic parameters may be at least 5 mm Hg, at least 6 mm Hg, at least 7 mm Hg, at least 8 mm Hg, at least 9 mm Hg, at least 15 mm Hg, at least 20 mm Hg or at least 25 mm Hg, and / or at least 5%, at least 10%, at least 15%, at least 25%, at least 30%, at least 35%, at least 40% or at least 50%.

[0141] Another aspect of the invention provides methods for using inhaled NO administration during adjustment and setting of LVAD parameters and hemodynamic medication and fluid replacement therapy once the acute effects of previous CPB on pulmonary hemodynamics have passed.

[0142] One current method of setting an LVAD involves setting the revolutions per minute (rpm) rate of an LVAD (e.g., a HeartMate II LVAD (HMII)) to provide adequate cardiac output and achieve optimal left ventricular decompression while maintaining a pulsatility index (defined as maximum LVAD flow rate minus minimum LVAD flow rate divided by average LVAD flow rate) of 3.5 to 4. Although modern "continuous flow" LVAD devices do not inherently have valves that open and close to produce pulsatile flow, the flow rate through these devices at any device setting varies according to the pressure gradient between the left ventricle and the aorta, such that the increased systolic pressure with each contraction of the left ventricle instantaneously increases the flow through the LVAD, thereby producing some pulsatile changes in blood flow. In addition, the fixed rate of a continuous flow LVAD is typically adjusted to maximize left ventricular decompression and improve cardiac output while allowing a minimum aortic valve opening ratio of 1:3 (i.e., left ventricular systolic pressure reaches a high enough pressure relative to aortic pressure to allow the aortic valve to open once in every three systoles, despite the continued outflow of blood through the LVAD).

[0143] Another current approach to LVAD setup involves optimizing the speed hemodynamically and using echocardiography at the time of LVAD placement, before the patient is discharged (i.e., after LVAD placement is permitted), and when clinical events such as new symptoms or aspiration events warrant further adjustments. However, these hemodynamic and echocardiographic assessments used to adjust LVAD settings are static in that they are performed at the time and conditions under which the test is performed (usually at rest) and at the left ventricular preload exhibited by the patient.

[0144] The use of inhaled NO during part of the test to maximally relax the pulmonary vasculature and reduce PVR will provide information about the maximum left ventricular preload that the right ventricle can produce without limitation by acute reversible pulmonary vasoconstriction. This dynamic (rather than static) assessment will provide additional information to optimize any specific set of LVAD settings to produce the desired cardiac output and pulsatility parameters while avoiding the generation of left ventricular suction as determined by simultaneous TTE. The novel use of inhaled NO as an adjunct to adjusting LVAD parameters will improve the efficiency and safety of a functional LVAD, which will improve cardiac output, pulsatility index, and exercise tolerance, and reduce the risk of right heart failure.

[0145] Because the prior art methods described above simply understand the extent to which LVAD and right ventricular settings and readings reflect the current level of PH without classifying PH as fixed versus reversible through dynamic testing, these methods limit the range of options for effective operation of LVAD function during the recovery period following LVAD implantation. Therefore, the more efficient and precise adjustment of LVAD parameters provided by this aspect of the invention can result in improved LVAD efficiency, cardiac output, end-organ perfusion, and exercise tolerance, and retesting and periodically resetting LVAD parameters using this paradigm can accelerate full recovery.

[0146] Thus, this aspect of the invention relates to methods for optimizing the settings of an LVAD by utilizing inhaled NO. In various embodiments of this aspect, the method includes administering inhaled NO to a patient with an LVAD; performing an echocardiogram or similar functional hemodynamic or cardiac imaging assessment on the patient during administration of inhaled NO; and adjusting or setting one or more parameters of the LVAD during the echocardiogram and during administration of inhaled NO. In one or more embodiments, adjusting or setting LVAD parameters during administration of NO helps optimize cardiac output, end-organ perfusion, LVAD efficiency, and / or exercise tolerance.

[0147] In one or more embodiments of this aspect, adjusting or setting one or more parameters of the LVAD includes one or more of: (i) determining a low pump speed setting for the LVAD based on a minimum pump speed required for the patient's aortic valve to open with each heartbeat or (ii) determining a high pump speed setting for the LVAD based on, for example, a pump speed at which the patient's heart septum flattens.

[0148] In some embodiments of this aspect, inhaled NO is applied at a concentration of 5 to 80 ppm for at least 10 minutes. Exemplary inhaled NO concentrations include about 5 ppm, about 10 ppm, about 15 ppm, about 20 ppm, about 25 ppm, about 30 ppm, about 35 ppm, about 40 ppm, about 45 ppm, about 50 ppm, about 55 ppm, about 60 ppm, about 65 ppm, about 70 ppm, and about 80 ppm. Exemplary NO application times include about 10 minutes, about 15 minutes, about 20 minutes, about 25 minutes, about 30 minutes, about 35 minutes, about 40 minutes, about 45 minutes, about 50 minutes, about 55 minutes, about 60 minutes, about 1.5 hours, about 2 hours, about 2.5 hours, and about 3 hours.

[0149] In some embodiments, the LVAD setting is changed by a series of incremental adjustments. For example, the LVAD pump speed can be adjusted upward in two or more steps. One or more or all of these steps can be performed during the administration of inhaled NO as described herein.

[0150] Another aspect of the invention provides for the long-term use of inhaled NO following LVAD implantation. In one or more embodiments of this aspect, if AVT favorably predicts that PH will resolve following continued use of the LVAD, and / or if the settings and readings and / or TTE indicate more effective LVAD function and hemodynamic status under inhaled NO stimulation, then the treating physician may wish to continue to administer inhaled NO to the patient during all or part of the recovery period. In various embodiments, inhaled NO will be administered to the patient during all or part of the day over a period of days, weeks, or months to maintain favorable LVAD function and / or hemodynamic status. As described above, periodic testing of starting and stopping inhaled NO over short periods of time can be performed so that when sufficient recovery has occurred such that inhaled NO no longer produces hemodynamic or TTE changes, inhaled NO can be carefully withdrawn from the patient. Such treatment is expected to improve cardiac output and exercise tolerance more quickly and reduce the risk of right heart failure.

[0151] In various embodiments of this aspect, the method comprises administering inhaled NO to a patient with an LVAD for at least 12 hours per day for at least 10 days. Inhaled NO may be administered for days to months or even longer. Exemplary treatment times include 10 days, 15 days, 20 days, 25 days, 30 days, 35 days, 40 days, 45 days, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 1 year, 1.5 years, or 2 years. In some embodiments, inhaled NO is administered to a patient indefinitely.

[0152] In some embodiments of this aspect, inhaled NO is applied at a concentration of 5 to 80 ppm for at least 12 hours per day. Exemplary inhaled NO concentrations include about 5 ppm, about 10 ppm, about 15 ppm, about 20 ppm, about 25 ppm, about 30 ppm, about 35 ppm, about 40 ppm, about 45 ppm, about 50 ppm, about 55 ppm, about 60 ppm, about 65 ppm, about 70 ppm, and about 80 ppm. Exemplary NO application times include about 12 hours per day, about 14 hours per day, about 16 hours per day, about 18 hours per day, about 20 hours per day, about 22 hours per day, or up to 24 hours per day.

[0153] Because patients with LVADs have pre-existing left ventricular dysfunction, it may be important to ensure that the LVAD is functioning properly prior to administering inhaled NO. Thus, in some embodiments, the method further comprises confirming that the LVAD is functioning properly prior to administering inhaled NO.

[0154] In one or more embodiments, inhaled NO is administered after the patient is weaned from cardiopulmonary bypass (CPB).

[0155] As an alternative to a constant concentration of NO, a dose of NO can be prescribed based on the patient's ideal body weight (IBW). Exemplary NO doses can range from about 25 to about 150 μg / kg IBW / h, such as about 25, about 30, about 35, about 40, about 45, about 50, about 60, about 70, about 80, about 90, about 100, about 110, about 120, about 130, about 140, or about 150 μg / kg IBW / h.

[0156] In one or more embodiments, the method further comprises monitoring one or more output parameters of the LVAD and / or one or more hemodynamic parameters of the patient, comparing the one or more output parameters and / or one or more hemodynamic parameters with a predetermined range, and adjusting the dose of inhaled NO if the one or more output parameters and / or one or more hemodynamic parameters are outside the predetermined range. In some embodiments, the method further comprises providing an alarm if the one or more output parameters and / or one or more hemodynamic parameters are outside the predetermined range. The dose of inhaled NO can be adjusted automatically (e.g., by a NO delivery device or a control system in communication with the NO delivery device), or can be adjusted manually by a physician or other user, e.g., in response to an alarm.

[0157] Examples of LVAD parameters that may be monitored include, but are not limited to, pump speed (eg, rpm), pump flow (eg, L / min), pump power, pulsatility index, battery charge, and LVAD status (eg, operational, whether an alarm is present).

[0158] In some embodiments, the LVAD has a minimum and / or maximum pump speed that is set by a physician and may be specific for an individual patient. Alternatively or additionally, the LVAD may also have a minimum and / or maximum pump speed set by the manufacturer of the LVAD. Regardless of whether the minimum and / or maximum pump speed is set by a physician or manufacturer, exemplary minimum pump speeds include 100 rpm, 200 rpm, 300 rpm, 400 rpm, 500 rpm, 6000 rpm, 700 rpm, 800 rpm, 900 rpm, 1,000 rpm, 1,500 rpm, 2,000 rpm, 2,500 rpm, 3,000 rpm, 4,000 rpm, 5,000 rpm, 6,000 rpm, 7,000 rpm, 8,000 rpm, 9,000 rpm, 10,000 rpm, 11,000 rpm, 12,000 rpm, 13,000 rpm, 14,000 rpm, 15,000 rpm, 16,000 rpm, 17,000 rpm, 18,000 rpm, 19,000 rpm, 20,000 rpm, 21,000 rpm, 22,000 rpm, 23,000 rpm, 24,000 rpm, 25,000 rpm, 26,000 rpm, 27,000 rpm, 28,000 rpm, 29,000 rpm, 30,000 rpm, 31,000 rpm, 32,000 rpm, 33,000 rpm, 34,000 rpm, 35 rpm, 13,000 rpm, 14,000 rpm, and 15,000 rpm, and exemplary maximum pump speeds include 1,000 rpm, 1,500 rpm, 2,000 rpm, 2,500 rpm, 3,000 rpm, 4,000 rpm, 5,000 rpm, 6,000 rpm, 7,000 rpm, 8,000 rpm, 9,000 rpm, 10,000 rpm, 11,000 rpm, 12,000 rpm, 13,000 rpm, 14,000 rpm, 15,000 rpm, 20,000 rpm, and 30,000 rpm. The minimum and maximum pump speeds may depend on the design of the LVAD.

[0159] Similarly, in some embodiments, the LVAD has a minimum and / or maximum pump speed set by a physician and may be specific for an individual patient. Alternatively or additionally, the LVAD may also have a minimum and / or maximum pump flow rate set by the manufacturer of the LVAD. Regardless of whether the minimum and / or maximum pump flow rate is set by a physician or manufacturer, exemplary minimum pump speeds include 1 L / min, 1.5 L / min, 2 L / min, 2.5 L / min, 3 L / min, 3.5 L / min, 4 L / min, 4.5 L / min, 5 L / min, 6 L / min, 7 L / min, 8 L / min, 9 L / min, and 10 L / min, and exemplary maximum pump flow rates include 3 L / min, 3.5 L / min, 4 L / min, 4.5 L / min, 5 L / min, 6 L / min, 7 L / min, 8 L / min, 9 L / min, 10 L / min, 11 L / min, 12 L / min, 13 L / min, 14 L / min, and 15 L / min. Minimum and maximum pump flows may depend on the design of the LVAD.

[0160] In some embodiments, the pulsatility index of the LVAD has minimum and / or maximum thresholds. As described above, the pulsatility index is the maximum pump flow minus the minimum pump flow, divided by the average pump flow. Since the pulsatility index is an indication of how much support the LVAD provides to the heart (a higher pulsatility index indicates that the LVAD provides more support), a high pulsatility index may be a cause for concern. Thus, exemplary maximum pulsatility indexes include values ​​of 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 20.

[0161] In some embodiments, the battery level of the LVAD is monitored. Since a low battery can indicate a future or imminent shutdown of the LVAD, when the battery level of the LVAD drops below a certain threshold, the inhaled NO dose can be reduced, a weaning protocol can be initiated, and / or an alarm can be provided. Examples of minimum battery levels include 30%, 25%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, or 1% battery remaining or 6 hours, 5 hours, 4 hours, 3 hours, 2 hours, 1 hour, 30 minutes, 20 minutes, 15 minutes, 10 minutes, 5 minutes, 4 minutes, 3 minutes, 2 minutes, or 1 minute of battery life remaining.

[0162] Similarly, other indicators of LVAD malfunction or complete LVAD failure can be monitored and the inhaled NO dose can be adjusted, a weaning protocol can be initiated and / or an alarm can be provided. Likewise, the inhaled NO dose can be adjusted automatically (e.g., by a NO delivery device or a control system in communication with the NO delivery device), or can be manually adjusted by a physician or other user.

[0163] Another aspect of the invention relates to a method for monitoring the left ventricle of a patient with an LVAD. In various embodiments of this aspect, the method includes reducing the pump rate of the LVAD or shutting down the LVAD; measuring one or more pulmonary hemodynamic parameters of the patient to obtain a first pulmonary hemodynamic value; preloading the left ventricle by administering inhaled NO to the patient; and measuring one or more pulmonary hemodynamic parameters of the patient after or during the administration of inhaled NO to obtain a second pulmonary hemodynamic value. In some embodiments, the pulmonary hemodynamic parameter is selected from LAP, PCWP, and CO, or can be any assessment of left ventricular reserve that is used to compensate for increased left ventricular preload that can be measured by right heart catheterization, echocardiography, MRI, or other techniques.

[0164] In some embodiments of this aspect, inhaled NO is applied at least 10 minutes at a concentration of 5 to 80 ppm. Exemplary inhaled NO concentrations include about 5 ppm, about 10 ppm, about 15 ppm, about 20 ppm, about 25 ppm, about 30 ppm, about 35 ppm, about 40 ppm, about 45 ppm, about 50 ppm, about 55 ppm, about 60 ppm, about 65 ppm, about 70 ppm, and about 80 ppm. Exemplary NO application time includes about 10 minutes, about 15 minutes, about 20 minutes, about 25 minutes, about 30 minutes, about 35 minutes, about 40 minutes, about 45 minutes, about 50 minutes, about 55 minutes, about 60 minutes, about 1.5 hours, about 2 hours, about 2.5 hours, about 3 hours, about 3.5 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, or about 8 hours.

[0165] According to one or more embodiments, an increase in LAP and / or PCWP of less than 5 mm Hg from a first pulmonary hemodynamic value to a second pulmonary hemodynamic value indicates that the left ventricle is improving. Other exemplary values ​​indicative of left ventricular improvement include an increase in LAP and / or PCWP of less than 1 mm Hg, 2 mm Hg, 3 mm Hg, 4 mm Hg, 6 mm Hg, 7 mm Hg, 8 mm Hg, 9 mm Hg, 10 mm Hg, 11 mm Hg, 12 mm Hg, 13 mm Hg, 14 mm Hg, or 15 mm Hg. In some embodiments, the method further includes changing treatment if the left ventricle is improving, such as removing the LVAD from the patient. Other modifications to treatment may include changing supportive medications (e.g., diuretics and / or positive inotropic drugs) given to the patient, such as reducing supportive medications.

[0166] Another aspect of the invention relates to a method of exercising the heart of a patient having an LVAD. In various embodiments of this aspect, the method comprises reducing and / or adjusting the pump speed of the LVAD or shutting down the LVAD; preloading the left ventricle by administering inhaled NO to the patient for at least 5 minutes; stopping the inhaled NO administration; and repeating the preloading and stopping to exercise the left ventricle of the patient's heart.

[0167] In some embodiments of this aspect, inhaled NO is applied at least 5 minutes at a concentration of 5 to 80 ppm. Exemplary inhaled NO concentrations include about 5 ppm, about 10 ppm, about 15 ppm, about 20 ppm, about 25 ppm, about 30 ppm, about 35 ppm, about 40 ppm, about 45 ppm, about 50 ppm, about 55 ppm, about 60 ppm, about 65 ppm, about 70 ppm, and about 80 ppm. Exemplary NO application time includes about 5 minutes, about 10 minutes, about 15 minutes, about 20 minutes, about 25 minutes, about 30 minutes, about 35 minutes, about 40 minutes, about 45 minutes, about 50 minutes, about 55 minutes, about 60 minutes, about 1.5 hours, about 2 hours, about 2.5 hours, about 3 hours, about 3.5 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, or about 8 hours.

[0168] Preloading of the left ventricle can be performed multiple times per day, such as twice a day, three times a day, four times a day, five times a day, six times a day, seven times a day, eight times a day, nine times a day, or ten times a day. Alternatively, preloading can be performed once a day. If preloading is performed multiple times a day, the preloading procedures can be concentrated together (e.g., separated by a few minutes or hours) or can be dispersed throughout the day. Preloading of the left ventricle can also be performed once a week, two days a week, three days a week, four days a week, five days a week, six days a week, or seven days a week. In an exemplary embodiment, the left ventricle is preloaded several times a day for several days a week, such as two to five times a day for two to four days a week, or other combinations of the above daily and weekly preloading schedules.

[0169] In some embodiments, the first instance or first few instances of left ventricular exercise of the patient are performed under the direct supervision of a physician, but once an appropriate exercise regimen has been determined for the patient, the exercise regimen can be performed under patient control or can be automated by the NO delivery device and / or control system.

[0170] Another aspect of the invention relates to methods for reducing the risk of adverse events during LVAD use. In particular, it is believed that inhaled NO can improve cardiovascular function in LVAD recipients with a functional LVAD, reduce the risk of adverse events associated with continuous-flow or semi-pulsatile LVADs (e.g., thrombosis, gastrointestinal bleeding), and improve the function of transplanted hearts by making the cardiovascular system more compliant.

[0171] A particular disadvantage of continuous-flow LVADs is that these devices produce reduced peripheral perfusion pulsatility as measured by pulsatility index, pulse pressure, and / or aortic valve opening frequency compared to pulsatile-flow LVAD devices and / or normal circulation from a well-functioning human heart, and this reduced pulsatility has been implicated in a number of adverse events, including decreased peripheral vascular compliance, gastrointestinal bleeding, arteriovenous malformations, hemolysis, pump thrombosis, aortic regurgitation, and reduced rate of left ventricular function recovery. These adverse events may also be associated with semi-pulsatile LVADs.

[0172] Evidence for microvascular dysfunction after continuous-flow LVAD support has been demonstrated using several sensitive techniques to assess postischemic flow autoregulation, including flow-mediated dilation (FMD) of the brachial artery and the reactive hyperemia index (RHI), both of which have been shown to be mediated primarily by locally released NO.

[0173] While not wishing to be bound by any particular theory, it is believed that the reduced pulsatility produced by the LVAD is associated with a disturbance in NO-mediated vascular autoregulation because pulsatile flow is considered a key generator of microvascular directional shear stress at the level of microvascular endothelial cells, which is closely related to the autoregulation of NO biology in the vascular system. Therefore, it is believed that at least some of the adverse events associated with continuous-flow LVADs and their reduced pulsatility may be secondary to impaired NO-mediated autoregulatory vascular function.

[0174] Shear stress and thus pulsatility are key factors in adapting organ perfusion to changes in cardiac output, perhaps in part through regulation of NO. Disrupted NO-mediated autoregulation of vascular function is reflected not only in the peripheral vasculature but also in the coronary vasculature, including association with higher rates of stent thrombosis after percutaneous coronary intervention. Impaired NO-mediated coronary vascular autoregulation is believed to provide a potential mechanism for reduced LV recovery during continuous LVAD support. NO not only mediates autoregulation of vascular tone but also regulates platelet activation and adhesion, such that disrupted NO regulation may contribute to the increased thrombosis associated with continuous-flow LVAD support. The attributes of NO-mediated vascular dysfunction are considered to be important overall risk factors for adverse cardiovascular outcomes in the general population. Indeed, some authors have suggested that impaired endothelial dilation is the ultimate cause of cardiovascular diseases such as coronary artery disease and peripheral artery disease. These broad effects of NO on vascular health are thought to be mediated in large part through regulation of oxidative stress through control of nitrosylation of multiple regulatory proteins.

[0175] Thus, in patients who rely on long-term continuous-flow LVAD support, inhaled NO may improve endothelial function and vascular health through two related and potentially complementary or synergistic mechanisms, thereby improving important clinical outcomes. First, as described above, by dilating the pulmonary vasculature, inhaled NO will increase left ventricular preload and improve left ventricular filling, thereby increasing the frequency of aortic valve opening and closing and, therefore, the pulsatility of any given LVAD speed setting. This effect may be more pronounced during rest or sleep, or during periods of increased cardiac output demands such as exercise, depending on the characteristics and settings of the LVAD device.

[0176] Second, by improving NO bioavailability throughout the peripheral and coronary circulation, inhaled NO also has the potential to improve NO-mediated vascular autoregulation and health, independent of its effects on circulating pulsatility. NO can be generated by NO synthase (NOS) or by the breakdown of nitrite or other compounds to NO. Even short-term (e.g., 2 h) inhalation of NO increases circulating levels of various molecules that have the potential to regenerate NO in the microcirculation, including nitrite (NO2 - ), nitrate (NO3 - ) and S-nitrosohemoglobin. These and other NO-derived molecules have been invoked in the beneficial so-called "distal effects" of inhaled NO. For example, inorganic nitrite is an endogenous substance produced by oxidation of NO under aerobic conditions (e.g., in the lungs), but conversely, under acidic conditions such as may exist in ischemic tissues, NO2 - It can be chemically and enzymatically reduced to NO, which has the beneficial effect of alleviating some of the consequences of ischemia, including ameliorating ischemia-reperfusion injury. Therefore, in the setting of endothelial dysfunction that occurs concurrently with prolonged continuous-flow LVAD support, inhaled NO is expected to improve and / or maintain tissue integrity and autoregulation of the peripheral vasculature and the tissues it supplies, including the myocardium, through a complex cascade of NO-mediated biochemical actions.

[0177] Thus, embodiments of the present invention provide for administration of NO by inhalation at doses and durations intended to achieve the following goals: (1) improving pulsatility through direct hemodynamic effects of NO on the pulmonary vasculature, thereby facilitating left ventricular filling, aortic valve opening and closing, thereby maximizing pulsatile flow and / or (2) providing NO precursors in the form of NO metabolites, such as NO2 - 、NO3 - , nitrosohemoglobin and other precursors, which are formed in the lungs as a result of NO inhalation and delivered through the circulation to peripheral tissues where NO can be re-formed, thereby further reducing endothelial dysfunction.

[0178] In various embodiments of this aspect, the method comprises administering inhaled NO to a patient with an LVAD for at least 12 hours per day for at least 10 days. Inhaled NO may be administered for days to months or even longer. Exemplary treatment times include 10 days, 15 days, 20 days, 25 days, 30 days, 35 days, 40 days, 45 days, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 1 year, 1.5 years, or 2 years. In some embodiments, inhaled NO is administered to a patient indefinitely.

[0179] In some embodiments of this aspect, inhaled NO is applied at a concentration of 5 to 80 ppm for at least 12 hours per day. Exemplary inhaled NO concentrations include about 5 ppm, about 10 ppm, about 15 ppm, about 20 ppm, about 25 ppm, about 30 ppm, about 35 ppm, about 40 ppm, about 45 ppm, about 50 ppm, about 55 ppm, about 60 ppm, about 65 ppm, about 70 ppm, and about 80 ppm. Exemplary NO application times include about 12 hours per day, about 14 hours per day, about 16 hours per day, about 18 hours per day, about 20 hours per day, about 22 hours per day, or up to 24 hours per day.

[0180] Because patients with LVADs have pre-existing left ventricular dysfunction, it may be important to ensure that the LVAD is functioning properly prior to administering inhaled NO. Thus, in some embodiments, the method further comprises confirming that the LVAD is functioning properly prior to administering inhaled NO.

[0181] In one or more embodiments, inhaled NO is administered after the patient is weaned from cardiopulmonary bypass (CPB).

[0182] As an alternative to a constant concentration of NO, a dose of NO can be prescribed based on the patient's ideal body weight (IBW). Exemplary NO doses can range from about 25 to about 150 μg / kg IBW / h, such as about 25, about 30, about 35, about 40, about 45, about 50, about 60, about 70, about 80, about 90, about 100, about 110, about 120, about 130, about 140, or about 150 μg / kg IBW / h.

[0183] In one or more embodiments, the method further comprises monitoring one or more output parameters of the LVAD and / or one or more hemodynamic parameters of the patient, comparing the one or more output parameters and / or one or more hemodynamic parameters with a predetermined range, and adjusting the dose of inhaled NO if the one or more output parameters and / or one or more hemodynamic parameters are outside the predetermined range. In some embodiments, the method further comprises providing an alarm if the one or more output parameters and / or one or more hemodynamic parameters are outside the predetermined range. The dose of inhaled NO can be adjusted automatically (e.g., by a NO delivery device or a control system in communication with the NO delivery device), or can be adjusted manually by a physician or other user, e.g., in response to an alarm.

[0184] Examples of LVAD parameters that may be monitored include, but are not limited to, pump speed (eg, rpm), pump flow (eg, L / min), pump power, pulsatility index, battery charge, and LVAD status (eg, operational, whether an alarm is present).

[0185] In some embodiments, the LVAD has a minimum and / or maximum pump speed that is set by a physician and may be specific for an individual patient. Alternatively or additionally, the LVAD may also have a minimum and / or maximum pump speed set by the manufacturer of the LVAD. Regardless of whether the minimum and / or maximum pump speed is set by a physician or manufacturer, exemplary minimum pump speeds include 100 rpm, 200 rpm, 300 rpm, 400 rpm, 500 rpm, 6000 rpm, 700 rpm, 800 rpm, 900 rpm, 1,000 rpm, 1,500 rpm, 2,000 rpm, 2,500 rpm, 3,000 rpm, 4,000 rpm, 5,000 rpm, 6,000 rpm, 7,000 rpm, 8,000 rpm, 9,000 rpm, 10,000 rpm, 11,000 rpm, 12,000 rpm, 13,000 rpm, 14,000 rpm, 15,000 rpm, 16,000 rpm, 17,000 rpm, 18,000 rpm, 19,000 rpm, 20,000 rpm, 21,000 rpm, 22,000 rpm, 23,000 rpm, 24,000 rpm, 25,000 rpm, 26,000 rpm, 27,000 rpm, 28,000 rpm, 29,000 rpm, 30,000 rpm, 31,000 rpm, 32,000 rpm, 33,000 rpm, 34,000 rpm, 35 rpm, 13,000 rpm, 14,000 rpm, and 15,000 rpm, and exemplary maximum pump speeds include 1,000 rpm, 1,500 rpm, 2,000 rpm, 2,500 rpm, 3,000 rpm, 4,000 rpm, 5,000 rpm, 6,000 rpm, 7,000 rpm, 8,000 rpm, 9,000 rpm, 10,000 rpm, 11,000 rpm, 12,000 rpm, 13,000 rpm, 14,000 rpm, 15,000 rpm, 20,000 rpm, and 30,000 rpm. The minimum and maximum pump speeds may depend on the design of the LVAD.

[0186] Similarly, in some embodiments, the LVAD has a minimum and / or maximum pump flow rate set by a physician and may be specific for an individual patient. Alternatively or additionally, the LVAD may also have a minimum and / or maximum pump flow rate set by the manufacturer of the LVAD. Regardless of whether the minimum and / or maximum pump flow rate is set by a physician or manufacturer, exemplary minimum pump speeds include 1 L / min, 1.5 L / min, 2 L / min, 2.5 L / min, 3 L / min, 3.5 L / min, 4 L / min, 4.5 L / min, 5 L / min, 6 L / min, 7 L / min, 8 L / min, 9 L / min, and 10 L / min, and exemplary maximum pump flow rates include 3 L / min, 3.5 L / min, 4 L / min, 4.5 L / min, 5 L / min, 6 L / min, 7 L / min, 8 L / min, 9 L / min, 10 L / min, 11 L / min, 12 L / min, 13 L / min, 14 L / min, and 15 L / min. Minimum and maximum pump flows may depend on the design of the LVAD.

[0187] In some embodiments, the pulsatility index of the LVAD has minimum and / or maximum thresholds. As described above, the pulsatility index is the maximum pump flow minus the minimum pump flow, divided by the average pump flow. Since the pulsatility index is an indication of how much support the LVAD provides to the heart (a higher pulsatility index indicates that the LVAD provides more support), a high pulsatility index may be a cause for concern. Thus, exemplary maximum pulsatility indexes include values ​​of 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 20.

[0188] In some embodiments, the battery level of the LVAD is monitored. Since a low battery can indicate a future or imminent shutdown of the LVAD, when the battery level of the LVAD drops below a certain threshold, the inhaled NO dose can be reduced, a weaning protocol can be initiated, and / or an alarm can be provided. Examples of minimum battery levels include 30%, 25%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, or 1% battery remaining or 6 hours, 5 hours, 4 hours, 3 hours, 2 hours, 1 hour, 30 minutes, 20 minutes, 15 minutes, 10 minutes, 5 minutes, 4 minutes, 3 minutes, 2 minutes, or 1 minute of battery life remaining.

[0189] Similarly, other indicators of LVAD malfunction or complete LVAD failure can be monitored and the inhaled NO dose can be adjusted, a weaning protocol can be initiated and / or an alarm can be provided. Likewise, the inhaled NO dose can be adjusted automatically (e.g., by a NO delivery device or a control system in communication with the NO delivery device), or can be manually adjusted by a physician or other user.

[0190] Another aspect of the invention provides a method for optimizing the dose of inspired NO for a continuous flow or semi-pulsatile LVAD to reduce the risk of adverse events during LVAD use and / or to optimize endothelial function.

[0191] In some embodiments of this aspect, the continuous flow LVAD setting is first optimized by conventional means and / or by the additional means described above to optimize dosing. Next, endothelial function can be measured, for example, by FMD and / or RHI. This adjustment may include introducing pulsatile modulation into the adjustment of continuous flow LVAD use and / or the use of enhanced external counterpulsation therapy (EECP therapy), which can be used with inhaled NO. Inhaled NO will start with one or more doses for different time periods, after which endothelial function will be remeasured using the same technique. Inhaled NO dosing will be modified in various stepwise ways to determine the optimal dosing paradigm to maximize the improvement of endothelial function. In addition, various NO-related molecules and other biomarkers of endothelial function will be measured in blood or plasma and correlated with RHI and / or FMD measurements to provide optimal monitoring of endothelial function to facilitate ongoing dose adjustments. This correlation can detect and / or determine the best parameters to be measured to ensure the most ideal inhaled NO dosing management to optimize and / or individualize inhaled NO dosing to maximize endothelial function in patients who rely on long-term continuous flow LVAD support.

[0192] In some embodiments of this aspect, inhaled NO is administered at an initial concentration of 5 to 80 ppm. Exemplary initial inhaled NO concentrations include about 5 ppm, about 10 ppm, about 15 ppm, about 20 ppm, about 25 ppm, about 30 ppm, about 35 ppm, about 40 ppm, about 45 ppm, about 50 ppm, about 55 ppm, about 60 ppm, about 65 ppm, about 70 ppm, and about 80 ppm.

[0193] As an alternative to a constant concentration of NO, a dose of NO may be prescribed based on the patient's ideal body weight (IBW). Exemplary initial inhaled NO doses may be in the range of about 25 to about 150 μg / kg IBW / h, such as about 25, about 30, about 35, about 40, about 45, about 50, about 60, about 70, about 80, about 90, about 100, about 110, about 120, about 130, about 140, or about 150 μg / kg IBW / h.

[0194] Exemplary increments for optimizing the inhaled NO dose include adjusting the NO concentration by 0.1 ppm, 0.2 ppm, 0.5 ppm, 1 ppm, 2 ppm, 3 ppm, 4 ppm, 5 ppm, 6 ppm, 7 ppm, 8 ppm, 9 ppm, 10 ppm, 15 ppm, and 20 ppm, or 0.1, 0.2, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, or 50 μg NO / kg IBW / h.

[0195] Once the inhaled NO dose is optimized, NO administration may continue during chronic LVAD use, eg, as described above.

[0196] Control System

[0197] The above methods can be implemented in one or more devices or systems using a combination of hardware and software. It should be understood that the control system as described herein can be an independent or separate hardware and software based device in communication with the LVAD and the NO delivery device, or the control system can be a primarily software-only implementation that resides on existing LVAD hardware, or the control system can be a primarily software-only implementation that resides on existing NO delivery device hardware.

[0198] In various embodiments, the control system includes appropriate components for sending and / or transmitting information and / or data between the NO delivery device, the LVAD, and the control system. Communication with the control system can be through a communication path, where the communication path can be wired or wireless, and where appropriate hardware, firmware, and / or software can be configured to interconnect the components and / or provide electrical communication through the communication path. For example, the communication path can be a wireless optical line-of-sight signal (e.g., an infrared signal) from one transceiver to another transceiver or from a transmitter to a receiver.

[0199] Control system hardware architecture:

[0200] Regardless of the integration technology (separate from or integrated with the LVAD or NO delivery device), the control system may include, for example, Figure 4 Some of the hardware components shown. Figure 4Configuration 1 includes a set of exemplary hardware elements for controlling a system. These elements may include a processing core that may be implemented using a microprocessor, microcontroller, field programmable gate array (FPGA), or other digital logic processing device. The control system may also include volatile and / or non-volatile memory, wherein the volatile memory allows efficient data processing and the latter resides to allow clinical scenarios or algorithms (codes) to be programmed into the present invention. Also resident are processor support functions for a clock (oscillator) and a safety monitor. As previously described, two-way data communications are provided with the LVAD and NO delivery device, or if the present invention is implemented as resident on the LVAD or NO device hardware, two-way data communications are simply provided with another system. A battery or wall power supply is provided to power the electronic device, and the battery or wall power supply can be shared with the LVAD or nitric oxide delivery device.

[0201] Figure 4 Configuration 2 of the present invention also provides a set of exemplary hardware elements for controlling the system, which is a more extensive configuration than configuration 1. In configuration 2, data is also exchanged with the Internet or cloud so that a physician can remotely view patient data and remotely adjust the LVAD or NO delivery device. It should be understood that analysis and / or optimization of treatment regimens specific to embodiments of the present invention can also be remotely provided to the physician ( For example , in the form of a cloud or Internet-based application, or as a program resident on a physician's laptop, tablet, smartphone, or other device) for patient status tracking or adjustment of treatment plans. Configuration 2 may also include a user interface for two-way information exchange with the patient (or caregiver).

[0202] If the control system is implemented as an integral part of a NO delivery device or LVAD, many, if not all, of the hardware elements described above may already reside on the NO delivery device or on the LVAD.

[0203] Control system input / output (IO) hardware:

[0204] Many processing tasks are unaffected and therefore may be equivalent whether the control system is stand-alone or resident on the LVAD or NO delivery device. However, certain tasks such as input / output routines and hardware-level code interaction related tasks (e.g., addressing of memory) may vary depending on whether the control system is stand-alone or resident on the LVAD or NO delivery device.

[0205] In the case of LVAD and NO device resident designs, the I / O hardware may include at least one bidirectional data port, and in the case of a stand-alone implementation, the I / O hardware may include at least two bidirectional data ports. It will be appreciated that the bidirectional data port is preferably an optically isolated serial port; however, other bidirectional data communication schemes including parallel ports, LAN, USB, etc. are also possible. Such bidirectional communication schemes are extensively described in the art. In addition, bidirectional communication can be achieved through wireless technology, such as through optical means such as infrared (IR) or through radio frequency (RF) means such as Bluetooth. Regardless of the communication technology, bidirectional data transmission preferably occurs in a timely manner.

[0206] Control system user interface hardware:

[0207] For control systems that reside on a NO delivery device or reside on a LVAD, the user interface can be integrated into the existing but expanded user interfaces of these devices. For example, if the control system is implemented on a NO delivery device, the control system may require additional settings, alarms, and modes that are not currently resident on such a NO delivery device, so the user interface of the NO delivery device can be expanded to incorporate such interactions. In addition, in the case of a control system that resides on an LVAD system, the LVAD system user interface can be modified to expand its functionality consistent with the new modes, alarms, and settings. In addition, many LVAD systems provide data displays on devices worn on the patient, and also provide clinician-mediated settings on auxiliary system monitors. It should be understood that the functionality of these auxiliary system monitor user interfaces can be expanded to accommodate the control system.

[0208] Finally, in some embodiments of the control system implemented on a stand-alone device, the user interface can have one of at least two configurations. The first configuration can include an auxiliary system monitor that the clinician uses to set up the system and then removes from the system after setting up and starting the system. This strategy is similar to Figure 4 Alternatively, the user interface may be integrated into the control system and worn by the user in the form of a module, preferably with a graphical display. This strategy is consistent with Figure 4 The more elaborate architecture of configuration 2 is consistent.

[0209] Control system remote connection hardware:

[0210] like Figure 4As shown, additional functionality can be added to the control system in the form of remote connection capabilities. The hardware used to implement this strategy may include a wired or wireless link connected to a computer with an Internet link or to a transceiver capable of remote information exchange, such as GSM or other remote wireless technologies that can be connected to the Internet or cloud infrastructure. It should also be understood that a secure / encrypted data link can be used to implement this remote information exchange. Other similar technologies are known to those skilled in the art and include, for example, current two-way Internet / cloud-based secure data exchange solutions, such as solutions based on, for example, Intel's Internet of Things (IoT) architecture and similar emerging architectures. The remote connection function can include a remote application programmed on a computer, mobile phone, smartphone, tablet computer or other device that receives information from the Internet or cloud and displays the information and allows two-way communication with the control system for many purposes, such as setting adjustments.

[0211] Control system software architecture:

[0212] The control system may include a software component that self-acts as a master over the functionality of the resident NO delivery device and / or LVAD controller. This software component may be responsible for controlling the NO delivery device and LVAD in an integrated manner consistent with the clinical scenarios described above and / or consistent with the user-specified controller functionality specified below.

[0213] Master-slave configuration

[0214] Whether the present invention resides on the NO delivery device, on the LVAD, or is independent, the control system is able to operate with the NO delivery device and the LVAD in a master / slave configuration. Specifically, the control system can play a primary role when an operating mode in which the control of the LVAD and the NO delivery device is controlled by the control system is adopted. This may include deleting the option of making setting adjustments to the LVAD or NO delivery device without overriding the master / slave configuration. This master / slave configuration can eliminate potential control ambiguity caused by adjustments to two or even three user interfaces. This master / slave configuration can be achieved by integrating additional code into the LVAD or NO delivery device to allow the master / slave configuration, or it can be achieved by allowing the control system to immediately override any setting changes made to the LVAD or NO delivery device. Finally, the master / slave configuration can be set and overridden by a clinician through the user interface screen of the control system, or remotely through a cloud / Internet-based application or through a resident application on a tablet, smart phone, laptop or other device.

[0215] Input / Output Parameters

[0216] The control system may utilize certain input parameters from the LVAD and / or NO delivery device, and the control system may include software functionality that is implemented in a manner that commands and controls various aspects of the LVAD and NO delivery device functions. In addition, a set of output parameters from the control system may be used so that the LVAD and NO delivery device can be commanded to perform certain tasks.

[0217] An exemplary set of input and output parameters is as follows Figure 5 As shown. For example, input parameters from the NO delivery device may include, but are not limited to, the patient's respiratory rate, the current NO delivery rate (e.g., ppm, mg / kg IBW / h, etc.), and / or the adverse event status of the NO delivery device. Exemplary input parameters from the LVAD include, but are not limited to, pump power, patient heart rate, blood flow through the pump, pulsatility index, LVAD pump speed, and / or the adverse event status of the LVAD. Exemplary output parameters from the control system to the NO delivery device include, but are not limited to, resetting / adjusting the NO delivery rate. Exemplary output parameters from the control system to the LVAD include, but are not limited to, resetting / adjusting the LVAD pump speed. Other related input / output parameters may also be used.

[0218] As described above, a control system that coordinates the operation of the LVAD and the NO delivery device can be used in any of the indications or methods described herein. In various embodiments of this aspect, the system includes a control system that is communicated with the NO delivery device and / or the LVAD, wherein the control system monitors one or more parameters of the NO delivery device and / or one or more parameters of the LVAD. If one or more parameters of the NO delivery device and / or the LVAD and / or the patient are outside a predetermined range, the control system can adjust the LVAD pump settings, inhale the NO dose, initiate a withdrawal scheme, and / or provide an alarm. The system may also include the NO delivery device and / or the LVAD itself.

[0219] In one or more embodiments, if a NO delivery device failure occurs that interrupts NO administration, the control system reduces the pump speed of the LVAD. The failure of the NO delivery device may be relatively minor or may be severe. The control system may also initiate a removal procedure for the NO delivery device if the LVAD fails and / or if the NO delivery device is about to be shut down or if the NO delivery device fails. The control system may also adjust the inhaled NO dose and / or provide an alarm if any monitored parameter is outside of a relevant range and / or if the LVAD and / or NO delivery device fails.

[0220] Once the clinician has entered a "rule set" for the control system and the clinician has activated the device, the control system can provide autonomous control of the LVAD and / or NO delivery device functions. The rule set may include initial LVAD and NO system settings, input and output parameter relationships, alarm settings, communication configurations, etc. It should be understood that the rule set can be entered interactively (for example, the pump speed can be adjusted during patient assessment), or the rule set can be pre-entered before the patient uses the device. The rule set can be accessed through a menu-driven software program that allows the clinician to enter all aspects of the desired system performance. Some of the rules entered by the clinician can be statically set, that is, the settings will not change once set. In some embodiments, a high pump speed alarm is an example of a static rule. The rules can define input and output relationships that vary over time; for example, the pump speed can be commanded to decrease over time or further, the rule set can allow the controller to control parameter changes within predetermined limits, or to control parameter changes through linear or nonlinear control techniques, in which the input / output parameter relationship can be dynamically controlled.

[0221] Menu-driven control mode

[0222] In one or more embodiments, the control system user interface allows selection of a plurality of menu-driven control schemes in which the operation of the NO delivery device and / or LVAD is controlled consistent with the clinical needs of the patient or clinician. An example of such a main user interface menu is Figure 6-8 For example, Figure 6 A menu is shown that allows the user to select a "mode" or control scheme, which can be any of the indications or methods described above. In some embodiments, when a particular mode is enabled, other modes are disabled, i.e., the modes are user accessible and exclusive. The menu may also include other user-settable parameters, such as alarm limits, NO delivery device and LVAD system configuration settings for treatment initiation, set-down parameters, or circumstances in which an active mode is disabled (e.g., when a mode is disabled, the configuration settings will be used as default settings). Figure 7 An exemplary alarm settings menu is shown, and Figure 8 Exemplary menus for setting NO delivery device and / or LVAD system configuration settings are shown. These menus may include submenus for setting alarms and / or configuration settings. In some embodiments, alarms, NO delivery device settings, and / or LVAD settings may disable some options based on mode selection. In addition, settings in these configuration submenus may allow for locking default settings, returning to the default settings when no mode selection options are active.

[0223] The exemplary modes are described in further detail below. These exemplary modes are not intended to be limiting, and fewer than all of these modes or additional modes may be provided in a menu-driven user interface of the control system.

[0224] Model 1: PH resolution potential (and heart transplant feasibility)

[0225] The Mode 1 submenu may include settings and operating procedures intended to determine a patient's hemodynamic response to the administration of inhaled NO to determine whether the patient's pulmonary hypertension can be resolved after continued use of the LVAD. In some embodiments, this mode may also be used to assess a patient's feasibility for cardiac transplantation. This mode may allow the user to enter relevant hemodynamic values ​​before and / or after the NO delivery settings are changed. The results may be based on clinical opinion, or the results may be compared to obtained clinical study data and predictions of patient outcomes provided by the software. Fig. 9 One embodiment of the program flow of the submenus associated with this mode is shown.

[0226] Mode 2: LVAD settings optimization

[0227] Mode 2 may include methods for determining upper and lower limits for LVAD pump rate operation concurrent with inspired NO delivery. Fig.10 One embodiment of the program flow of the submenus associated with this mode is shown. In this mode, the pump speed (or possibly other LVAD parameters) is adjusted during the administration of NO so that cardiac output can be optimized. Specifically, in this mode, echocardiography is used to determine a low pump speed setting corresponding to the minimum pump speed required to open the aortic valve with each heartbeat, and a high pump speed is also determined at which the heart septum flattens. In this mode, the user is prompted to make an initial nitric oxide setup and subsequent pump speed adjustments in the software. The software ultimately records a target pump speed for use.

[0228] Model 3: Optimization of right ventricular function during LVAD use

[0229] Mode 3 may provide a method to reduce the risk of right ventricular failure during LVAD use based on simultaneous delivery of nitric oxide with LVAD use by making setting adjustments to NO dose and LVAD settings. Fig.11 An embodiment of the program flow of the submenus related to this mode is shown. These settings can be adjusted manually (such as Fig.11 ), or can be adjusted by a user-defined control system and user-defined transfer functions and dynamic performance characteristics (see Fig.11 Monitoring of the patient may be performed by any number of clinical techniques including hemodynamic assessment. Finally, alarm limits for the measured LVAD and NO delivery device parameters may be set.

[0230] Mode 4: Left ventricular function assessment

[0231] Mode 4 can be used to assess the status of left ventricular function after the LVAD pump setting has been reduced or completely stopped. Fig.12 An embodiment of the program flow of the submenus related to this mode is shown. Ventricular function can be evaluated by measuring hemodynamic parameters such as LAP, PCWP or CO. Finally, the ventricular function can be evaluated by intelligent algorithms (see Fig.12 The penultimate box in ) optionally evaluates changes in hemodynamic parameters before and after pump speed adjustment, and the algorithm provides clinical feedback based on these hemodynamic changes regarding the left ventricular state.

[0232] Mode 5: Cardio workout facility

[0233] Mode 5 can be used to exercise the heart by first reducing the speed of the LVAD pump or stopping the LVAD pump, then preloading the left ventricle with a short-term administration of NO, and then cycling the NO dose off and on to exercise the (left ventricle) heart. An exemplary submenu for implementing this mode is shown below: Fig.13 shown.

[0234] Mode 6: Global control system settings

[0235] Mode 6 can be used to set up a control system that can oversee the functions of the NO delivery device and / or LVAD. This control system setting can be set as the main control system that is always used during operation of the present invention, or it can be disabled in the specific modes previously described. The control system setting can provide Figure 5 A method of adjusting the nitric oxide dose or LVAD pump speed based on the input parameters specified in, or the hemodynamic parameters measured by the clinician at appropriate intervals. In this mode, the clinician can be allowed to specify the input parameters and the transfer function between single or multiple input parameters and output parameters (such as pump speed and NO dose). The dynamic performance of this relationship can also be specified by the user. Finally, timed NO pulsatile delivery synchronized with the respiratory cycle can also be specified. This can include single or multiple NO pulsations with fixed or time-varying concentration distribution curves. It can also be specified that the clinician can turn on the controller (to make the output parameter change over time) or disable the controller to support static (output) setting adjustments. These settings can be displayed in the main menu screen together with the measured parameters and alarm settings (as specified in another main menu item) so that the clinician can quickly assess the patient's status at a glance.

[0236] LVAD

[0237] The LVAD can be any suitable LVAD prescribed by a physician, including but not limited to a pulsatile, semi-pulsatile (e.g., an LVAD that performs pulsatile pump speed modulation), or a continuous flow LVAD. The LVAD can have any suitable blood flow providing mechanism, including but not limited to a valve, a centrifugal pump, a turbine, etc. The LVAD can be internal or external to the patient. In some embodiments, the LVAD is an internal LVAD implanted in the patient.

[0238] NO delivery device

[0239] The NO delivery device may include any suitable components for administering inhaled NO to a patient, including flow sensors, valves, flow controllers, processors, safety shutoff valves, purge valves, tubing, etc. The NO delivery device may administer a constant concentration of inhaled NO, as described in U.S. Pat. No. 5,558,083, the entire contents of which are incorporated herein by reference. An example of such a NO delivery device is Figure 1 As shown. The NO delivery device can apply multiple pulses of inhaled NO to provide a dose of inhaled NO that is independent of the patient's breathing pattern, such as described in U.S. Pat. No. 7,523,752, the entire contents of which are incorporated herein by reference. An example of such a NO delivery device is Figure 2 As shown. The NO delivery device may also have the features described in any of the following U.S. patents and published U.S. patent applications, which are incorporated herein by reference in their entirety: U.S. Patent No. 8,573,209; U.S. Patent No. 8,573,210; U.S. Patent No. 8,770,199; and U.S. Patent Application Publication No. 2014 / 0283828. Other suitable NO delivery devices are known in the art, such as INOmax DS and / or

[0240] exist Figure 1 In the exemplary NO delivery device shown, a therapeutic injector module 103 is in fluid communication with a first inlet 101 and a second inlet 102. The first inlet 101 is in fluid communication with a therapeutic gas injection tube 110, which is in fluid communication with a therapeutic gas supply source containing NO. The second inlet 102 is in fluid communication with a respiratory gas delivery system 111, which is shown as a ventilator. Figure 1The arrows in indicate the flow direction of the breathing gas and the combined gas mixture of the therapeutic gas and the breathing gas. The flow sensor 106 is in fluid communication with the second inlet 102 and is downstream of the second inlet 102, and monitors the flow of the breathing gas through the therapeutic injector module 103. A top view of the therapeutic injector module 103 is shown. The therapeutic gas and the breathing gas are mixed in the therapeutic injector module 103 to provide a gas mixture. The injector module cable 105 connects the therapeutic injector module 103 to the control module 109. The control module 109 includes a display 108, which can display information about NO delivery and / or any parameters described herein, and can provide any alarms as described herein. The inspiratory breathing hose 112 is in fluid communication with the outlet 104 and the nasal cannula 114 or other patient interface. The inspiratory breathing hose provides the gas mixture of the breathing gas and the therapeutic gas to the nasal cannula 114, which delivers the gas mixture to the patient. The patient gas sampling line 113 diverts some of the gas mixture flow from the inspiratory breathing hose 112 and brings it to the sample block 119 to measure the NO, O2 and / or NO2 concentration in the gas delivered to the patient.

[0241] exist Figure 2 In the exemplary NO delivery device shown, the supply tank 220 may be in fluid communication with a tank pressure gauge 221 and a regulator 223 to reduce the tank pressure to the operating pressure of the gas delivery device 222. The drug gas may enter the gas delivery device 222 through an inlet 224, which may provide a ready connection between the delivery device 222 and the supply tank 220 through a conduit. The gas delivery device 222 may have a filter 225 to ensure that no contaminants may interfere with the safe operation of the device and / or a pressure sensor 227 to detect whether the supply pressure is sufficient and may therefore include a gas shut-off valve 226 to control the entry of drug gas into the delivery device 222 and provide safety control in the event that the delivery device 222 over-delivers drug gas to the patient. In the event of such over-delivery, the shut-off valve 226 may be immediately closed and an alarm 242 may be sounded to make the user aware that the gas delivery device has been disabled. Thus, the shut-off valve 226 may be a solenoid valve that may operate according to a signal directed by a central processing unit including a microprocessor.

[0242] Downstream of the shutoff valve 226 may be a flow control system that controls the flow of medication gas to the patient through the gas conduit 219 of the patient device 218 to the patient 241. In an exemplary embodiment, the flow control system may include a first flow control valve and a second flow control valve, the first flow control valve may be a high flow control valve 228, the second flow control valve may be a low control valve 230, and there may be a first flow orifice that is a high flow orifice 232, and a second flow orifice that may be a low flow orifice 234. The purpose and use of the flow valves 228, 230 and the flow orifices 232, 234 will be explained later. An air flow sensor 236 may also be located in the flow of medication gas to the patient device 218, and as shown, may be located downstream of the flow control system, however, the air flow sensor 236 may alternatively be located upstream of the flow control system.

[0243] Next, there may be a patient triggered sensor 238. When the patient inhales during inspiration, it may create a small sub-atmospheric pressure in the nose or other area where the patient device 218 is located and therefore in the patient device 218 itself. The patient triggered sensor 238 may detect this pressure drop and may provide a signal indicating that the patient has begun to inhale. Similarly, when the patient exhales, there may be a positive pressure in the patient device 218, and the patient triggered sensor 238 may detect this positive pressure and may provide a signal indicating that exhalation has begun. This may allow the patient triggered sensor 238 to determine not only the patient's breathing rate, but also the inspiratory time and / or expiratory time. It should be understood that other techniques may be used to determine the patient's breathing rate, inspiratory time, expiratory time, and / or other aspects of the patient's breathing.

[0244] There may also be a central processing unit (CPU) 240 that can communicate with the patient trigger sensor 238, the flow valves 228, 230, the gas shut-off valve 226, and other components to perform various exemplary embodiments of the present disclosure. The CPU 240 may include a processing component such as a microprocessor to perform all solutions to the equations that may be used by the gas delivery device 222 to deliver a predetermined amount of drug gas to the patient. The CPU 420 may be connected to the front panel 210 where the user can enter settings and monitor therapy.

[0245] like Figure 3 As shown, the NO delivery device can be connected to the LVAD. Figure 3 In the illustrated embodiment, the control system is integrated with the NO delivery device. However, as described above, the control system may also be integrated with the LVAD, or may be a separate stand-alone control module.

[0246] The NO delivery device may also include components for monitoring the gas applied to the patient, such as gas concentration sensors (e.g., O2, NO and / or NO2 sensors), sampling pumps, etc. The NO delivery device may also include redundant sensors and / or valves and have an automatic backup delivery system in the event of a failure of the primary NO delivery system. The NO delivery device may also include one or more sensors for feedback control of NO delivery and / or for independent safety monitoring of NO delivery. The NO delivery device may also provide an alarm if any monitored parameter reaches or exceeds a certain level or if there are other safety issues.

[0247] The NO delivery device can be portable and lightweight (e.g., less than 10 pounds) so that it does not hinder the patient's mobility. The NO delivery device can be battery-operated and have a battery life that meets certain minimum standards, such as having a battery life of at least 16 hours. The NO delivery device can also include a backup battery or other power source.

[0248] The NO source may include two or more cylinders so that continuous NO administration is not interrupted when one of the cylinders is replaced. Also, instead of a cylinder containing NO gas, NO may be generated at the bedside, for example by an appropriate chemical reaction, such as a reaction of a NO-releasing agent and a reducing agent such as ascorbic acid. Other methods for generating nitric oxide at the bedside are also known in the art.

[0249] The NO delivery device may also include an automatic pre-use checkout procedure with automatic purge for purging NO2, and on-screen setup instructions. The system may also have on-screen alert help and wireless connectivity to communicate with an electronic medical record (EMR) system or technical support desk for remote troubleshooting. Another safety feature may be the incorporation of sensors and mechanisms that automatically detect fluid or gas leaks.

[0250] The NO delivery device may have additional safety features, such as a withdrawal scheme that slowly reduces the inhaled NO dose to avoid a sudden increase in PAP. Such a withdrawal scheme may be initiated by a "withdrawal button" on the NO delivery device, or may be automatically initiated by a control system that is communicated with the LVAD and / or the NO delivery device. The withdrawal scheme may include slight changes in the NO dose, such as reducing the dose by 5ppm for a few minutes, then reducing the dose by another 5ppm for a few minutes until the patient is completely weaned from inhaled NO. Other increments of the withdrawal scheme include 0.1ppm, 0.2ppm, 0.5ppm, 1ppm, 2ppm, 3ppm, 4ppm, 5ppm, 6ppm, 7ppm, 8ppm, 9ppm, 10ppm, 15ppm and 20ppm or 0.1, 0.2, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40 or 50μg / kg IBW / h. Multiple withdrawal schemes may be used based on the detected fault and whether the device shutdown is significant. The weaning regimen can also be individualized for a particular patient, for example by making the weaning regimen dependent on the patient's current and / or prior degree of PH.

[0251] As described above, in some embodiments, the inhaled NO dose is adjusted in response to monitoring various parameters of the LVAD and / or the patient. These adjustments may include an increase or decrease in the inhaled NO dose (in ppm or μg / kg IBW / h). The increments of the adjustments include 0.1ppm, 0.2ppm, 0.5ppm, 1ppm, 2ppm, 3ppm, 4ppm, 5ppm, 6ppm, 7ppm, 8ppm, 9ppm, 10ppm, 15ppm and 20ppm, or 0.1, 0.2, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40 or 50μg / kg IBW / h.

[0252] According to the present invention, a method for determining whether a patient with pulmonary hypertension will resolve the pulmonary hypertension by continuing to use a left ventricular assist device (LVAD) is provided. The method may include measuring one or more pulmonary hemodynamic parameters of a patient with an LVAD to obtain a first pulmonary hemodynamic value; after obtaining the first pulmonary hemodynamic value, administering inhaled nitric oxide to the patient with the LVAD; and measuring one or more pulmonary hemodynamic parameters of the patient during or after the administration of inhaled nitric oxide to obtain a second pulmonary hemodynamic value. A reduction in a pulmonary hemodynamic parameter from the first pulmonary hemodynamic value to the second pulmonary hemodynamic value of at least 10 mm Hg and / or at least 20% indicates that the patient may resolve the pulmonary hypertension after continuing to use the LVAD.

[0253] The method may further include selecting a pulmonary hemodynamic parameter from mean pulmonary artery pressure (mPAP), transpulmonary gradient (TPG), and pulmonary vascular resistance (PVR). The method may further include administering nitric oxide at a concentration of 5 to 80 ppm for at least 10 minutes.

[0254] According to the present invention, the method may include measuring one or more pulmonary hemodynamic parameters by performing right heart catheterization. If the decrease in the pulmonary hemodynamic parameter from a first pulmonary hemodynamic value to a second pulmonary hemodynamic value is at least 10 mm Hg and / or at least 20%, the patient may be placed on a heart transplant list. The LVAD may be removed and a donor heart implanted in the patient.

[0255] According to the present invention, a method for optimizing the settings of a left ventricular assist device (LVAD) is provided. The method may include administering inhaled nitric oxide to a patient with an LVAD; performing an echocardiogram on the patient during the administration of the inhaled nitric oxide; and adjusting or setting one or more parameters of the LVAD during the echocardiogram and during the administration of the inhaled nitric oxide to optimize cardiac output. Adjusting or setting one or more parameters of the LVAD includes one or more of the following: (i) determining a low pump speed setting for the LVAD based on the minimum pump speed required for the patient's aortic valve to open with each heartbeat or (ii) determining a high speed setting for the LVAD based on the pump speed at which the patient's heart septum flattens. The inhaled nitric oxide can be administered at a concentration of 5 to 80 ppm for at least 10 minutes.

[0256] According to the present invention, a method for reducing the risk of right ventricular failure during the use of a left ventricular assist device (LVAD) is provided. The method may include administering inhaled nitric oxide to a patient with an LVAD for at least 12 hours a day for at least 20 days to reduce the risk of right ventricular failure, and confirming that the LVAD is functioning before administering inhaled nitric oxide. Inhaled nitric oxide can be administered after the patient is removed from cardiopulmonary bypass (CPB), and can be administered for at least 30 days, or at least 3 months. Inhaled nitric oxide can be administered at a concentration of 5 to 80 ppm or at a dose of 25 to 150 μg / kg IBW / h.

[0257] The method may further include monitoring one or more output parameters of the LVAD and / or one or more hemodynamic parameters of the patient, comparing the one or more output parameters and / or the one or more hemodynamic parameters to predetermined ranges, adjusting the dose of inhaled nitric oxide if the one or more output parameters and / or the one or more hemodynamic parameters are outside the predetermined ranges, and providing an alarm if the one or more output parameters and / or the one or more hemodynamic parameters are outside the predetermined ranges.

[0258] According to the present invention, a method for monitoring the left ventricle of a patient with a left ventricular assist device (LVAD) is provided. The method may include reducing the pump rate of the LVAD or shutting down the LVAD; measuring one or more pulmonary hemodynamic parameters of the patient to obtain a first pulmonary hemodynamic value; preloading the left ventricle by administering inhaled nitric oxide to the patient; and measuring one or more pulmonary hemodynamic parameters of the patient after or during the administration of inhaled nitric oxide to obtain a second pulmonary hemodynamic value. The pulmonary hemodynamic parameters may be selected from left atrial pressure (LAP), pulmonary capillary wedge pressure (PCWP), and cardiac output (CO). Inhaled nitric oxide may be administered at a concentration of 5 to 80 ppm for at least 10 minutes. If the left ventricle is improving, treatment may be changed by removing the LVAD from the patient. An increase of less than 5 mm Hg in LAP and / or PCWP from a first pulmonary hemodynamic value to a second pulmonary hemodynamic value may indicate that the left ventricle is improving.

[0259] According to the present invention, a method of exercising the heart of a patient having a left ventricular assist device (LVAD) is provided. The method may include reducing the pump rate of the LVAD or shutting down the LVAD; preloading the left ventricle by administering inhaled nitric oxide to the patient for at least 5 minutes; stopping the administration of inhaled nitric oxide; and repeating the preloading and stopping to exercise the left ventricle of the patient's heart. Preloading the left ventricle may include administering inhaled nitric oxide at a concentration of 5 to 80 ppm for a period of 5 to 30 minutes, and may be performed one to five times per day.

[0260] According to the present invention, a method for reducing the risk of adverse events during the use of a continuous flow or semi-pulsatile left ventricular assist device (LVAD) is provided. The method may include administering inhaled nitric oxide to a patient with a continuous flow or semi-pulsatile LVAD for at least 12 hours a day for at least 20 days. Adverse events may be associated with reduced pulsatility and / or with impaired NO-mediated vascular function. Prior to administering inhaled nitric oxide, the function of the LVAD may be confirmed. Inhaled nitric oxide may be administered after cardiopulmonary bypass (CPB) is removed from the patient and may be administered for at least 30 days or 30 months. Inhaled nitric oxide may be administered at a concentration of 5 to 80 ppm or at a dose of 25 to 150 μg / kg IBW / h.

[0261] The method may also include monitoring one or more output parameters of the LVAD and / or one or more hemodynamic parameters of the patient, comparing the one or more output parameters and / or the one or more hemodynamic parameters to a predetermined range, and adjusting the dose of inhaled nitric oxide if the one or more output parameters and / or the one or more hemodynamic parameters are outside of the predetermined range. An alarm may be provided if the one or more output parameters and / or the one or more hemodynamic parameters are outside of the predetermined range.

[0262] According to the present invention, a method for optimizing the dose of inhaled nitric oxide used with a continuous flow or semi-pulsatile left ventricular assist device (LVAD) is provided. The method may include measuring endothelial function in a patient with a continuous flow or semi-pulsatile LVAD; administering inhaled nitric oxide to the patient at a first dose; measuring the patient's endothelial function during the administration of inhaled nitric oxide; and adjusting the dose of inhaled nitric oxide to optimize endothelial function. Measuring the patient's endothelial function includes measuring one or more of (i) flow-mediated dilation (FMD) or (ii) reactive hyperemia index (RHI).

[0263] The method may include measuring one or more NO-related molecules and / or other biomarkers of endothelial function in the patient's blood and / or plasma. The NO-related molecule may be selected from nitrite (NO2 - ), nitrate (NO3 - ) and nitrosohemoglobin.

[0264] According to the present invention, a system is provided. The system may include a control system connected to a nitric oxide delivery device and / or a left ventricular assist device (LVAD), wherein the control system monitors one or more parameters of the nitric oxide delivery device and / or one or more parameters of the LVAD, and provides an alarm if one or more parameters of the nitric oxide delivery device and / or the LVAD are outside a predetermined range. If the nitric oxide delivery device fails, the control system may reduce the pump speed of the LVAD. If the LVAD fails, the control system may initiate a removal procedure for the nitric oxide delivery device. The control system may be integrated with the nitric oxide delivery device, integrated with the LVAD, or a component of an independent control module. The system may include a nitric oxide delivery device and a LVAD.

[0265] Reference throughout this specification to "one embodiment," "certain embodiments," "one or more embodiments," or "an embodiment" means that a particular feature, structure, material, or characteristic described in connection with the embodiment is included in at least one embodiment of the present invention. Thus, the appearance of phrases such as "in one or more embodiments," "in certain embodiments," "in an embodiment," or "in an embodiment" in various places throughout this specification are not necessarily referring to the same embodiment of the present invention. Furthermore, the particular features, structures, materials, or characteristics may be combined in any suitable manner in one or more embodiments.

[0266] Although the present invention has been described herein with reference to specific embodiments, it should be understood that these embodiments are merely illustrative of the principles and applications of the present invention. It will be apparent to those skilled in the art that various modifications and changes may be made to the methods and apparatus of the present invention without departing from the spirit and scope of the present invention. Therefore, it is intended that the present invention include modifications and changes within the scope of the appended claims and their equivalents.

[0267] Appendix 1

[0268] Data review and bibliography

[0269] Use in premature neonates

[0270] Prophylactic or therapeutic use in premature infants is not approved by the U.S. Food and Drug Administration (FDA). Therefore, safety and effectiveness are considered to have not been established. For this reason, Ikaria does not recommend the use of this drug in such applications, and all diagnostic, preventive, and therapeutic decisions in this population must be delegated solely to clinicians.

[0271] INOmax is not approved for use in premature infants, children, or adults.

[0272] introduction

[0273] An estimated 12.18% of all births in the United States in 2009 resulted in preterm birth (<37 weeks gestation), placing these infants at high risk for severe morbidity and mortality. 1 Preterm neonates are particularly vulnerable to long-term neurocognitive and medical impairments, including chronic lung disease (CLD) such as bronchopulmonary dysplasia (BPD). 2 Before the routine use of exogenous surfactant and antenatal steroid therapy, the fibrosis and inflammation associated with this diagnosis were primarily attributed to barotrauma and oxygen toxicity. 2,3 The lungs of infants who recently died from BPD showed less fibrosis than has been found historically. 3 Common findings include abnormal alveolarization and pulmonary microvascular development and decreased vascular endothelial growth factor (VEGF) and its receptor, suggesting that other pathogenic factors need to be investigated. 3

[0274] In multiple studies, the use of inhaled nitric oxide (NO) in animals treated with VEGF receptor antagonists appears to promote the growth of pulmonary blood vessels and alveoli. 4-7 Thus, protecting the premature lung from injury and promoting normal lung maturation now represent two possible approaches by which the outcome of neonates at risk for BPD may be improved. To date, several preliminary clinical studies have evaluated the safety and efficacy of inhaled NO for the prevention of BPD in premature infants with complex outcomes.8-15 Doses ranged from 5 to 20 ppm, however, it remains unclear which dose should be considered optimal in this population. Overall, subjects with less severe respiratory distress appeared to show some benefit, while subjects with the greatest degree of prematurity had lower success rates. These data broaden the understanding of the complex pathogenic mechanisms that lead to the development of BPD and prompt researchers to explore whether changes in treatment-related variables such as timing, dose, and duration of NO therapy may be beneficial in optimizing treatment outcomes.

[0275] Table of contents

[0276] Appendix 1

[0277] Data review and bibliography

[0278] Use in premature neonates

[0279] NIH Consensus Statement......................................7

[0280] Cole et al., 2011..................................7

[0281] Meta-analysis......................................8

[0282] Askie et al., 2011................................8

[0283] Donohue et al., 2011.................................8

[0284] Barrington&Finer, 2010........................9

[0285] Hoehn et al., 2006................................9

[0286] Hoehn et al., 2000...................................9

[0287] EUNO(MERCIER, 2010)........................10

[0288] Durrmeyer X,2013................................11

[0289] NO CLD(BALLARD RA,2006).........................13

[0290] Banks,1999......................................14

[0291] Kaplan,2006.....................................15

[0292] Ballard PL,2007.................................15

[0293] Di Fiore,2007...................................16

[0294] Truog,2007......................................16

[0295] Ballard PL,2008.................................17

[0296] Hibbs,2008......................................17

[0297] Keller,2009a....................................18

[0298] Keller,2009b....................................18

[0299] Posencheg,2010..................................19

[0300] Ballard PL,2010.................................19

[0301] Walsh,2010......................................20

[0302] INO (KINSELLA,2006)..........................21

[0303] Kinsella,2009...................................21

[0304] Watson,2009.....................................22

[0305] Gadhia,2014.....................................2

[0306] INNOVO(FIELD,2005).............................24

[0307] Ahluwalia,2006...................................25

[0308] Hoo,2009........................................2

[0309] Huddy,2008.......................................25

[0310] HASCOET,2005…………………………….27

[0311] Hamon,2005......................................27

[0312] December,2004...................................2

[0313] Hamon,2009a.....................................29

[0314] Hamon, 2009b........................................29

[0315] Hascoet, 2009....................................29

[0316] NICHD-PINO(VAN MEURS,2005)......................31

[0317] Van Meurs, 2007..................................32

[0318] Van Meurs, 2005....................................32

[0319] Chock, 2008........................................32

[0320] Ambalavanan, 2008...............................33

[0321] Gordon, 2006.....................................33

[0322] Hintz, 2006.......................................34

[0323] Sokol, 2006........................................34

[0324] Hintz, 2007.......................................35

[0325] SCHREIBER, 2003....................................37

[0326] Srisuparp,2002..................................38

[0327] Izhar, 2001........................38

[0328] Izhar, 2000........................38

[0329] Appendix 1

[0330] Data review and bibliography

[0331] Use in premature neonates

[0332] Mestan, 2005................................39

[0333] White, 2010................................40

[0334] Cooper, 2011................................41

[0335] Patrianakos-Hoobler, 2011........................42 French-Belgian collaboration NO trial group (MERCIER, 1999)...43

[0336] Truffert, 2003................................43

[0337] AIKIO et al., 2012..................................55

[0338] SHARMA et al., 2011..................................56

[0339] Dewhurst et al., 2010...............................57

[0340] O'DONNELL, FRANTA and MILETIN, 2010..................57

[0341] Hopper et al., 2009.................................58

[0342] SU&CHEN,2008....................................58

[0343] KHEMANI et al., 2007................................59

[0344] Kumar et al., 2007..................................60

[0345] TANAKA et al., 2007.................................60

[0346] DANI et al., 2006................................61

[0347] Lindwall et al., 2005..................62

[0348] ATHAVALE et al., 2004..................62

[0349] UGA et al., 2004.................................63

[0350] AIKIO et al., 2003..................................63

[0351] CLARK PL et al., 2002...............................64

[0352] Truog et al., 2002..................................64

[0353] DU et al., 2002................................65

[0354] KINSELLA et al., 1999...............................65

[0355] YADAV&EMMERSON, 1999........................66

[0356] Cheung et al., 1998.................................67

[0357] Laubscher et al., 1997...............68

[0358] SKIMMING et al., 1997...............................68

[0359] SUBHEDAR, RYAN, SHAW, 1997........................69

[0360] SUBHEDAR&SHAW, 1997........................69

[0361] BENNETT et al., 2001................................70

[0362] VAN MEURS et al., 1997..............................70

[0363] PELIOWSKI et al., 1995..............................71

[0364]

[0365]

[0366]

[0367]

[0368]

[0369]

[0370]

[0371]

[0372]

[0373]

[0374]

[0375]

[0376]

[0377]

[0378]

[0379]

[0380]

[0381]

[0382]

[0383]

[0384]

[0385]

[0386]

[0387]

[0388]

[0389]

[0390]

[0391]

[0392]

[0393]

[0394]

[0395]

[0396]

[0397]

[0398]

[0399]

[0400]

[0401]

[0402]

[0403]

[0404]

[0405]

[0406]

[0407]

[0408]

[0409]

[0410]

[0411]

[0412]

[0413]

[0414]

[0415]

[0416]

[0417]

[0418]

[0419]

[0420]

[0421]

[0422]

[0423]

[0424] Appendix 1

[0425] Data review and bibliography

[0426] Use in premature neonates

[0427] EUNO (European Union Nitric Oxide): INOT-27 Study

[0428] Mercier et al., 2010 (main phase)

[0429] Mercier et al. conducted a prospective, randomized, multicenter, double-blind, placebo-controlled study to evaluate the safety and efficacy of inhaled nitric oxide (NO) in reducing the risk of BPD in 800 premature infants with a gestational age range of 24 to 60 years with respiratory distress. +0 to 28 +6 week. 15 If ultrasound was not available, gestational age could be determined by first-trimester ultrasound or last menstrual period. Subjects with mild to moderate respiratory failure (FiO2 ≥ 0.30, mean airway pressure ≥ 4 cm H20 to maintain SpO2 ≥ 85%) were included if they required surfactant or required continuous positive airway pressure (CPAP) within 24 hours after birth. Out-of-hospital infants with a gestational age of ≥ 29 years or a birth weight < 500 gm were excluded, as were infants who required FiO2 > 0.5 to maintain SpO2 > 85% at adequate airway pressure to achieve adequate chest expansion two hours after administration of exogenous surfactant. Other exclusion criteria included: substantial congenital heart disease (other than patent ductus arteriosus), pulmonary hypoplasia; severe bleeding or coagulopathy with a high diathesis risk; a decision to discontinue further treatment due to severe birth anomalies, or use of study drugs or devices before or during the study.

[0430] In this intention-to-treat (ITT) population, 399 subjects were randomized to the NO group, while 401 subjects were included in the placebo group. Subjects received 5 ppm NO or placebo (nitrogen) for 7-21 days, and treatment was started early (2-26 hours after birth). If the subject required mechanical ventilation for <7 days, the study gas was administered via nasal cannula (NC) or nasal continuous positive airway pressure (nCPAP). The primary efficacy outcome was determined as survival at 36 weeks of postmenstrual gestational age without BPD, grouped by age and birth weight. Secondary outcomes included: survival without substantial brain damage; number of days on mechanical ventilation; length of hospital stay; and safety endpoints included the incidence of periventricular leukomalacia (PVL), intraventricular hemorrhage (IVH), treated arterial catheter, perforation / sepsis, pneumothorax, pulmonary hemorrhage, retinopathy of prematurity (ROP), or necrotizing enterocolitis (NEC).

[0431] No statistically significant between-group differences were found in baseline characteristics, as shown in Table 1 below.

[0432] Table 1: Baseline characteristics

[0433]

[0434] Appendix 1

[0435] Data review and bibliography

[0436] Use in premature neonates

[0437]

[0438] SD = standard deviation; CPAP = continuous positive airway pressure

[0439] There were no significant between-group differences (P=0.73) in the primary efficacy outcome (overall treatment success), as measured by survival to 36 weeks postmenstrual gestational age (PMA) without the development of BPD. Complete primary outcome data are reported in Table 2 below.

[0440] Table 2: Main efficacy results

[0441]

[0442] PMA = postmenstrual gestational age; n = number; RR = relative risk; CI = confidence interval; BPD = bronchopulmonary dysplasia; g = grams; N / A = not provided by the authors

[0443] Although the success rate was higher in women (NO: 133 of 189 [70%]; placebo: 121 of 181 [67%]) compared with men (NO: 125 of 206 [61%]; placebo: 141 of 219 [64%]), the

[0444] Data review and bibliography

[0445] Use in premature neonates

[0446] A relative risk associated with treatment was found (women: 1.18, 95% CI 0.76-1.83, vs men: 0.85, 95% CI 0.58-1.26). Subjects of older gestational age (≥26 weeks gestational age) were more likely to survive without BPD than those of younger gestational age, but neither showed a benefit from NO. Higher survival without BPD was observed in black subjects treated with NO compared with non-black subjects, although the difference was not significant. Secondary outcomes related to survival without parenchymal brain damage (parenchymal brain damage was defined as grade 3 or 4 intraventricular hemorrhage, periventricular hemorrhage, or periventricular leukomalacia based on head ultrasonography) are recorded in Table 3 below.

[0447] Table 3: Secondary outcomes related to survival without parenchymal brain damage

[0448]

[0449] NO = inhaled nitric oxide; RR = relative risk; CI = confidence interval

[0450] Of the 800 subjects, 792 (99%) received treatment. The mean ± SD duration of treatment was 16.3 ± 6.5 days in the NO group and 16.4 ± 6.6 days in the placebo group. When subjects who died during treatment were excluded, the mean duration of treatment was 17.3 ± 5.9 days in the NO group and 17.4 ± 5.9 days in the placebo group. Other secondary results are shown in Table 4.

[0451] Table 4: Other secondary outcomes

[0452]

[0453] Appendix 1

[0454] Data review and bibliography

[0455] Use in premature neonates

[0456] No significant between-group differences were found in the incidence of grade 1 IVH (all 5%), grade 2 IVH (all 11%), grade 3 IVH (NO: 12%; placebo: 9%), or grade 4 IVH (all 0%). Low PVL rates were also reported in the NO (2%) and placebo (<1%) groups. By the 36-week time point, a total of 56 of 399 (14%) subjects in the NO group had died, compared with 42 of 401 (10%) placebo subjects (P = 0.21). In the safety population, the most common causes of death were: intracranial hemorrhage, sepsis, and pulmonary hemorrhage, with no significant differences in incidence between the groups. Details of the reported serious adverse events are shown in Table 5 below.

[0457] Table 5: Secondary outcomes: serious adverse events (safety population)

[0458]

[0459] Overall, survival without chronic lung disease did not differ significantly between groups, and neither gestational age nor birth weight influenced treatment outcomes. Similarly, early low-dose inhaled nitric oxide did not alter the incidence of intraventricular hemorrhage or periventricular leukomalacia. After a comprehensive review of the data and consultation with multiple clinical experts in the therapeutic area, the sponsor's assessment was that the data from this single study did not represent a safety signal and that there was no reasonable possibility that the observed difference in mortality was related to NO treatment. Although the actual reason, if any, for the apparent imbalance is unclear, other confounding factors including low birth weight, gestational age, and site-related factors offer alternative explanations. The researchers concluded that the use of 5 ppm NO, initiated within the first 24 hours of life and continued for a median of 3 weeks, does not improve survival without BPD in extremely premature neonates with mild to moderate respiratory failure. Long-term follow-up is planned for this study, including neurological assessments at 2 and 7 years of age, with pulmonary function testing at 7 years of age.

[0460] NO CLD (Nitric Oxide for the Prevention of Chronic Lung Disease)

[0461] Ballard, RA et al., 2006 (main phase)

[0462] Ballard and colleagues conducted a randomized, group-based, double-blind, multicenter, placebo-controlled trial of 582 preterm infants (7 to 21 days of age) who required ventilatory support. < The effect of inhaled nitric oxide (NO) on improving survival without bronchopulmonary dysplasia (BPD; also known as chronic lung disease) was evaluated in 184 women (1250 g, mean gestational age [GA] 26 weeks). 13,14 Subject to Appendix 1

[0463] Data review and bibliography

[0464] Use in premature neonates

[0465] Subjects were randomized (median age at enrollment, 16 days) to receive NO or placebo; randomization of infants was divided into groups according to birth weight (500-799g and 800-1250g). In the case of multiple births, the first infant was randomized, and all siblings were non-randomly assigned to the same treatment group. The dose of NO was started at 20 ppm for 48 to 96 hours; the dose was subsequently reduced to 10, 5, and 2 ppm at weekly intervals, with a minimum treatment duration of 24 days. The primary endpoint was survival without BPD (requiring ventilatory support or inability to maintain oxygen saturation >88% while breathing room air) at 36 weeks postmenstrual gestational age.

[0466] At baseline, there were no significant differences between the study groups in gestational age, birth weight, sex, race or ethnicity, or preexisting medical conditions. The mean birth weights of infants treated with NO and placebo were 766 g and 759 g, respectively; the median respiratory severity score was 3.5 (equivalent to an oxygenation index [OI] between 5 and 9) in both groups. No significant between-group differences were found between subjects receiving mechanical ventilation (high-frequency and conventional) and those receiving nasal continuous airway pressure (nCPAP). The outcome data are shown in Table 6 below.

[0467] Table 6: Results

[0468]

[0469] NO = inhaled nitric oxide; CI = confidence interval; BPD (bronchopulmonary dysplasia

[0470] Among subjects with a birth weight of 500-799 g, neonates treated with NO were discharged from the hospital earlier (P = .04) and received supplemental oxygen therapy for a shorter period of time (P = .006). The primary outcome remained significant when nonrandomized siblings were excluded (relative benefit, 95% CI, 1.01 to 1.53, P = .035). At 40 and 44 weeks PMA, significantly fewer NO subjects remained in the hospital or required respiratory support (mechanical ventilation, nCPAP, or supplemental oxygen) compared with control subjects (40 weeks: P = .01; 44 weeks: P = .03). If BPD occurred, it was less severe in subjects in the NO group compared with controls, and by 52 weeks PMA, most subjects had been discharged from the hospital or no longer required respiratory support. In a post hoc analysis, a similar relationship was observed with Appendix 1

[0471] Data review and bibliography

[0472] Use in premature neonates

[0473] Compared with placebo, NO significantly improved survival without BPD in infants enrolled 7 to 14 days of age (49.1% vs. 27.8%; P = .005), but not in infants enrolled 15 to 21 days of age (40.7% vs. 42.8%). Ballard and colleagues concluded that in this preterm population, chronic NO treatment initiated between 7 and 21 days of age significantly improved survival without short-term adverse events or bronchopulmonary dysplasia.

[0474] Early inhaled nitric oxide therapy in premature infants with respiratory failure

[0475] Kinsella et al., 2006 (5 ppm; 21-day treatment)

[0476] Kinsella and colleagues conducted a randomized, multicenter trial to evaluate the role of low-dose NO in preterm neonates (n = 793; birth weight 500 to 1250 g, mean GA 25.6 weeks) with respiratory failure (RF) and requiring mechanical ventilation (conventional or high-frequency). 16 Subjects were randomized (mean age at randomization approximately 30 hours) to receive either NO 5 ppm or placebo for 21 days (or until extubation); randomization was divided according to birth weight (500-749 g, 750-999 g, and 1000-1250 g). The primary outcome measure was a composite endpoint of death or BPD (requiring supplemental oxygen or mechanical ventilation plus abnormal chest x-ray findings at 36 weeks postmenstrual gestational age). Other outcomes included severe (grade 3 or 4) intracranial hemorrhage (ICH), periventricular leukomalacia (PVL), and ventriculomegaly. Mean birth weights of infants treated with NO and placebo were 796 g and 788 g, respectively; baseline OI was 5.4 and 5.8, respectively.

[0477] Overall, the incidence of the combined endpoint of death or BPD did not differ significantly between NO and placebo (71.6% vs. 75.3%; RR 0.95, 95% CI 0.87 to 1.03; P = 0.24); however, in the group of infants with a birth weight of 1000 to 1250 g, NO was associated with a significant reduction in the combined primary endpoint (38.5% vs. 64.1%; RR 0.60, 95% CI 0.42 to 0.86; P = 0.004) and BPD alone (29.8% vs. 59.6%; RR 0.50, 95% CI 0.32 to 0.79; P = 0.001). In the other birth weight groups, there were no significant between-group differences in the incidence of the primary endpoint or BPD. No significant differences were found between NO and placebo subjects in any of the secondary outcomes, including the incidence of air leaks (6.3% vs. 6.1%, P=0.94); pulmonary hemorrhage (6.0% vs. 6.6%, P=0.75); patent ductus arteriosus (PDA) requiring medical therapy (54.0% vs. 53.7%, P=0.92); PDA requiring surgical ligation (21.6% vs. 21.8%, P=0.96); necrotizing enterocolitis (14.0% vs. 12.5%, P=0.54); retinopathy of prematurity requiring intervention (16.6% vs. 15.2%, P=0.59); use of postnatal corticosteroids (60.2% vs. 55.9%, P=0.24); use of medications at 36 weeks (P>0.30); or use of medications among survivors (P>0.25). In the entire cohort, NO was also associated with a significant reduction in PVL (5.2% vs. 9.0%; RR 0.58, 95% CI 0.33 to 1.00; P = 0.048), and in the composite endpoint of severe ICH, PVL, and ventriculomegaly (17.5% vs. 23.9%; RR 0.73, 95% CI 0.55 to 0.98; P = 0.03) compared with placebo.

[0478] Appendix 1

[0479] Data review and bibliography

[0480] Use in premature neonates

[0481] Kinsella and colleagues concluded that NO did not reduce the overall incidence of respiratory failure and BPD in premature infants with a birth weight of 500 to 1,250 g. However, the risk of BPD was reduced in the subgroup of neonates weighing at least 1,000 g at birth and resulted in a reduced risk of brain damage in the entire population.

[0482] INNOVO: Neonatal ventilation with inhaled nitric oxide versus ventilatory support without inhaled nitric oxide for the treatment of severe respiratory failure in premature infants

[0483] Field et al., 2005 (5-40 ppm, study period up to 12 hours, NO treatment beyond this time point)

[0484] In a randomized, multicenter, controlled, open-label trial, Field and colleagues evaluated the role of NO in preterm infants (n = 108; GA < 34 weeks and < 28 days of age) with severe RF who required conventional or high-frequency ventilatory support (and received surfactant when appropriate) (a parallel study was conducted in term neonates, n = 60, but is not reported here). 17 Preterm subjects were randomized to ventilatory support with NO 5ppm (n=55) or without NO (n=53). The dose of NO could be increased to a maximum of 40ppm to achieve a satisfactory response (PaO2>22.5mmHg increase after 15 minutes). Although this was not a crossover trial, 3 subjects in the NO group died before receiving NO, and 4 subjects in the non-NO group were administered NO at the discretion of the clinician. The primary outcome was death or severe disability at one year corrected age, death or CLD before discharge (36 weeks postmenstrual gestational age and / or supplemental oxygen on the expected day of delivery). Secondary outcomes included: length of hospital stay; duration of ventilation and oxygen; adverse events; age at determination of full oral feeding; 1-year corrected neurodevelopmental and psychomotor outcomes, respiratory status, and hospitalization. The results are provided in Tables 7 and 8 below.

[0485] Table 7: Results related to NO administration

[0486]

[0487] Appendix 1

[0488] Data review and bibliography

[0489] Use in premature neonates

[0490]

[0491] a=PaO2 increased by <3 kPa but increased by 27% from baseline; b=NO discontinuation: coagulopathy; c=data missing for 5 NO subjects and 4 non-NO subjects who were discharged to home oxygen; d=intraventricular hemorrhage involving brain parenchyma (n=2); intraventricular hemorrhage with platelet aggregation problems; coagulopathy; subcutaneous hemorrhage; and airway secretions.

[0492] Adverse events reported by NO subjects compared with non-NO subjects included: pneumothorax (20 in each group); pulmonary haemorrhage (4 and 5, respectively); patent ductus arteriosus requiring treatment (9 and 13, respectively); confirmed infection (23 and 21, respectively); suspected infection (12 and 17, respectively); retinopathy of prematurity (8 and 4, respectively); and serious brain abnormalities on ultrasound scan at day 7 and / or 36 weeks (6 of 27 and 10 of 21, respectively).

[0493] Table 8: Status of 1-year follow-up actions

[0494]

[0495] Appendix 1

[0496] Data review and bibliography

[0497] Use in premature neonates

[0498]

[0499] At baseline, infants had a median OI of 32 and a mean GA of 27 weeks; birth weights were 1066 g and 890 g in the NO and no-NO groups, respectively. Of 108 participants, 64 (59%) died, and 37 of 44 survivors (84%) had some type of injury, of whom 9 (20%) were classified as severely disabled. Treatment with NO was not associated with a significant effect on any of the prespecified primary outcomes: death or severe disability at one year corrected age (RR 0.99, 95% CI 0.76 to 1.29; P = 0.94); death or supplemental oxygen on the expected day of delivery (RR 0.84, 95% CI 0.68 to 1.02; P = 0.08); or death or supplemental oxygen at 36 weeks postmenstrual gestational age (RR 0.98, 95% CI 0.87 to 1.12; P = 0.80). For death, the RR for NO was 0.85 (95% CI 0.62 to 1.16; P = 0.30). A trend was noted for NO subjects to spend more time on the following behaviors: ventilation (log rank: 1.4; P = 0.06); supplemental oxygen (log rank: 1.4; P = 0.24); and hospital (log rank: 3.5; P = 0.06); however, this primarily reflected subjects who died (P = 0.05; log rank test). In contrast, these durations tended to be shorter in survivors who received NO. Field and colleagues concluded that the evidence from this trial does not support the hypothesis that NO improves outcomes in preterm neonates with severe respiratory failure, but they suggest that the use of NO in less severely ill preterm infants may help reduce the risk of chronic lung disease. Further trials are recommended to confirm these findings.

[0500] Hascoet et al., Safety and efficacy of nitric oxide therapy in preterm infants.

[0501] (10 tertiary perinatal centres in France and Belgium, July 1999 to February 2001)

[0502] Hascoet et al., 2005 (Editorial comment: Finer et al., 2005)

[0503] Hascoet and colleagues conducted a randomized, multicenter trial to evaluate the role of low-dose NO (5 ppm) in preterm infants (GA < 32 weeks). 18 Gestational age <32 weeks was a single inclusion criterion, and subjects were admitted if they had refractory hypoxemia (PO2 <50 and PCO2 <50 mm Hg, FiO2 = 1.0), thrombocytopenia <50,000 / mm 3 , or severe fetal abnormalities, they were excluded. Of a total of 860 preterm neonates (NO, n = 415; controls, n = 445), 61 NO subjects (40% < 28 weeks of gestation) and 84 control subjects (45% < 28 weeks of gestation) also had HRF. NO was started at 5 ppm and Appendix 1

[0504] Data review and bibliography

[0505] Use in premature neonates

[0506] Maintained for the first hour, subsequent dose adjustments were determined by the aAO2 response (positive response: increase in aAO2 >22; intermediate response: aAO2 <22 but decrease ≥25%). If the response was positive, NO was reduced to 2 ppm and withdrawn after 2 hours. The dose was maintained at 5 ppm and reassessed every two hours if the response was intermediate. If no response was found, NO was increased to 10 ppm for 2 hours and reassessed. In the event of treatment failure, subjects were withdrawn after 4 hours. The primary outcome was defined as intact survival at 28 days of age (i.e., no respiratory support, oxygen supplementation, or IVH>grade I, nor refractory hypoxemia).

[0507] There was no difference in the primary outcome between the NO and control groups (61.4% [23% with HRF] vs. 61.1% [21.4% with HRF], P = 0.943); however, this finding involved a larger population of subjects (n = 860), many of whom were not eligible for the randomized intervention. There were no significant between-group differences in intraventricular hemorrhage (6% vs. 7%); patent ductus arteriosus (34% vs. 37%), or necrotizing enterocolitis (8% vs. 6%). Compared with nonhypoxemic neonates, control subjects with HRF (OR = 3.264 [CI 1.461 to 7.292]) had a significantly increased risk of BPD compared with subjects with HRF who received NO (OR = 1.626 [CI 0.633 to 4.178]). Hascoet et al. concluded that NO treatment appears to be safe in preterm neonates but did not result in a significant survival benefit at 28 days, although subjects who responded to NO had better outcomes than those with moderate or no response. The authors note that a larger sample size may be needed to demonstrate an improvement in overall outcomes. In an accompanying editorial, Finer comments that the interpretation of these findings is further limited by (among other factors) the relatively high rate of open-label NO use during the study period. 93

[0508] NICHD PiNO (National Institute of Child Health and Human Development Trial of Inhaled Nitric Oxide for the Treatment of Severe Respiratory Failure in Preterm Infants) with a concurrent pilot trial in older preterm neonates

[0509] Van Meurs et al., 2005 (Main Phase, NICHD PiNO Study)

[0510] Van Meurs et al conducted a randomized, multicenter, blinded, placebo-controlled trial in preterm neonates (n = 420; GA < 34 weeks, birth weight 401 to 1,500 g) with severe RF (post-surfactant OI ≥ 10x2) to determine the safety and efficacy of treatment with NO compared with placebo. 11,91(2004 Abstract LB12 presented at the Annual Meeting of the Pediatric Academic Societies). (Note: After the Data Safety and Monitoring Board found higher than expected mortality in both treatment groups in an interim analysis, the initial OI requirement of OI ≥10x2 between 30 minutes and 12 hours was adjusted to OI ≥5 between 30 minutes and 24 hours, followed by a second OI ≥7.5. Analyses were then grouped according to OI criteria). Eligible infants were those who required assisted ventilation and had a diagnosis of respiratory distress syndrome (RDS), sepsis or pneumonia, aspiration syndrome, idiopathic persistent pulmonary hypertension, or suspected pulmonary hypoplasia. Subjects were randomized to receive NO or placebo. The dose of NO was started at 5 ppm and could be increased to 10 ppm to achieve a complete response (increase in PaO2 >20

[0511] Appendix 1

[0512] Data review and bibliography

[0513] Use in premature neonates

[0514] mm Hg); weaning occurred 10 to 14 hours after initiation of therapy. The primary endpoint was BPD (defined as oxygen therapy at 36 weeks of gestation) or death (occurring before hospital discharge or within 365 days for hospitalized infants).

[0515] Baseline characteristics were similar between treatment groups. Mean birth weight and gestational age in the NO group (n = 210; 840 ± 264 g; 26 ± 2 weeks) were not significantly different from those in the placebo group (n = 210; 837 ± 260 g; 26 ± 2 weeks). Mean age at randomization for NO subjects was 26 ± 23 hours with an OI of 23 ± 17, whereas for placebo subjects it was 28 ± 22 hours with a mean OI of 22 ± 17.

[0516] The trial was terminated prematurely after the second planned interim analysis because 67% of the enrolled infants had reached the study endpoint (death, discharge to home, or 365 days of age). The mean OI at randomization was 24.6 in group 1 and 20.4 in group 2 (due to modified criteria after the first interim analysis). Thirty minutes after the start of treatment, NO treatment was associated with significant improvements in PaO2 and OI compared with placebo (P<0.001 for both). At follow-up, there was no significant difference between NO and placebo in the incidence of the primary outcome (80% vs. 82%; RR 0.97, 95% CI 0.86 to 1.06; P=0.52). The BPD rates were 60% and 68% for NO and placebo, respectively (RR 0.90, 95% CI 0.75 to 1.08; P = 0.26); the mortality rates were 52% and 44%, respectively (RR 1.16, 95% CI 0.96 to 1.39; P = 0.11). There were no significant differences between NO and placebo subjects in the following secondary outcomes: incidence of grade 3-4 IVH or PVL (39% and 32%, respectively; RR 1.25, 95% CI 0.95 to 1.66, P = 0.11); days on oxygen (84 ± 63 vs 91 ± 61 days, respectively, P = 0.91); physiologic BPD (50% and 60%, respectively; RR 0.87, 95% CI 0.68 to 1.10, P = 0.17); length of hospital stay (101 ± 47 vs 111 ± 48 days, respectively, P = 0.65); days on mechanical ventilation (39 ± 45 vs 47 ± 53 days, respectively, P = 0.56); and air leak (35% vs 32%, respectively, RR 0.84, 95% CI 0.68 to 1.10, P = 0.17). 1.12, 95% CI 0.78 to 1.61, P = 0.55); or threshold retinopathy of prematurity (30% vs 32%, respectively, RR 1.16, 95% CI 0.81 to 1.64, P = 0.42).

[0517] In a post hoc analysis, a significant reduction in the risk of the primary endpoint was observed in infants with birth weight >1,000 g treated with NO compared with placebo (50% vs. 69%; RR 0.72, 95% CI 0.54 to 0.96; p = 0.03); however, weight < Infants treated with 1,000 g of NO had higher rates of mortality (RR 1.28, 95% CI 1.06 to 1.54; p = 0.01) and severe intraventricular hemorrhage (IVH) or PVL (RR 1.40, 95% CI 1.03 to 1.88; p = 0.03). Conventional ventilation was found to be significantly associated with higher mortality (p = 0.01). The rates of severe IVH or PVL in the overall population did not differ significantly between the groups.

[0518] Van Meurs, 2007 (Concurrent pilot study of larger preterm neonates)

[0519] In a separate but concurrent small pilot study of 29 older preterm neonates (<34 GA; birth weight >1,500 g) with severe respiratory failure (OI ≥15x2), Van Meurs and colleagues evaluated the safety and efficacy of NO use. 10 Eligible subjects require mechanical ventilation and have a basic diagnosis of RDS, pneumonia and / or sepsis, special Appendix 1

[0520] Data review and bibliography

[0521] Use in premature neonates

[0522] pulmonary hypertension, aspiration syndrome, or suspected pulmonary hypoplasia. All had to have received ≥1 dose of surfactant 4 hours prior to fulfilling the OI requirement. (Note: the initial OI requirement of OI ≥15x2 between 30 minutes and 12 hours was adjusted to OI ≥10x2 between 30 minutes and 24 hours after the Data Safety and Monitoring Board found higher than expected mortality in both treatment groups in an interim analysis. Analyses were then grouped according to the OI criteria). Subjects were excluded if they developed congenital heart disease, thrombocytopenia, bleeding diathesis, or a decision was made to discontinue complete treatment. Subjects were randomized to receive NO treatment (n=14; males, n=10), starting at 5 ppm (with the possibility of increasing to 10 ppm if necessary) or placebo (n=15; males, n=9), and treatment continued up to 14 days. The primary outcome was death and / or BPD, and secondary outcomes included the incidence of grade 3-4 IVH or PVL; oxygen days; duration of hospitalization and ventilation; incidence of air leaks and retinopathy of prematurity.

[0523] No statistically significant between-group differences were found in baseline characteristics, with the majority of subjects diagnosed with RDS (NO, n=11; placebo, n=11) and without aspiration syndrome. Before discharge, 36% of NO subjects (n=5) and 27% of control subjects (n=4) died. No significant differences were reported in the primary and secondary outcomes at the end of the study (before or after adjustment for the OI registry stratum). After adjustment for OI, the adjusted relative risks of death and / or BPD were reported as RR 0.80, 95% CI 0.43 to 1.48, P=0.50; death alone as RR 1.26, 95% CI 0.47 to 3.41, P=0.65; and BPD alone as RR 0.40, 95% CI 0.47 to 3.41, P=0.21. Although the differences were not significant, no grade 3-4 IVH / PVL or air leaks were reported in the NO group, whereas IVH / PVL and air leaks were reported in both control subjects. Ventilation days (P = 0.08) and hospital stay (P = 0.10) were shorter in the NO group (8.7 ± 5.4 days; 36.0 ± 21.8 days) compared with the control group (16.8 ± 13.9 days; 68.5 ± 58.3 days). Methemoglobin levels remained ≤ 4% and NO2 levels ≤ 3 ppm in both groups for all subjects. Protocol deviations from open-label NO use were noted in two control subjects and one subject characterized as a NO nonresponder. Van Meurs and colleagues concluded that in this pilot study, the use of NO did not result in a significant reduction in the incidence of death and / or BPD before and after adjustment for OI grouping, but suggested that further studies with larger sample sizes are needed to confirm these results.

[0524] Schrieber and colleagues study preterm birth

[0525] Schreiber et al., 2003 (10 ppm on day 1, followed by 5 ppm x 6 days: Effect of NO on CLD / mortality)

[0526] Schreiber and colleagues conducted a randomized, single-center, double-blind, placebo-controlled, 2×2 factorial design trial in preterm infants with RDS (n = 207; GA < 34 weeks, < 72 hours of age, birth weight < 2,000 g) who required mechanical ventilation and surfactant therapy. 8 Inclusion criteria included: need for endotracheal intubation and mechanical ventilation and exogenous surfactant,

[0527] Appendix 1

[0528] Data review and bibliography

[0529] Use in premature neonates

[0530] Neonates with severe congenital anomalies or fetal hydrops were excluded. Neonates were randomized to receive NO (n=105) or placebo (n=102) and intermittent mandatory ventilation (IMV) or high-frequency oscillatory ventilation (HFOV). Treatment with NO was initiated at a dose of 10 ppm on the first day (12 to 24 hours) by continuous inhalation, followed by 5 ppm for 6 days. The ventilation strategy was determined by the clinician according to the protocol and could be changed during the study if the clinician believed that the subject's condition was severe enough to necessitate a replacement. If this occurred, the study gas was discontinued. Subjects who died before discharge or after six months, whichever was later, were included in the analysis.

[0531] The primary outcome measure was death or chronic lung disease (CLD), and secondary outcomes included duration of mechanical ventilation and hospitalization. Additional post hoc analyses were performed to assess the impact of ventilator strategy, birth weight, and initial lung disease severity on the primary outcome. Adverse events, including IVH, PVL, pulmonary interstitial emphysema, pneumothorax, and patent ductus arteriosus requiring indomethacin or surgery, were also captured and assessed. Methemoglobin levels were measured daily, and it was recommended to stop study gas if the concentration exceeded 5%.

[0532] At baseline, the median OI was 6.94, and the mean birth weight was 1,017 g (NO) and 949 g (placebo). The primary outcome (death or CLD) was significantly reduced in the NO group (48.4%) compared with the placebo group (63.7%) (RR 0.76, 95% CI 0.60 to 0.97; P = 0.03) and there were no significant differences between the two groups according to birth weight (P = 0.36). In a post hoc analysis, among infants with a baseline OI below the median, NO significantly reduced the risk of the primary outcome compared with placebo (RR 0.53, 95% CI 0.35 to 0.81), but no significant association was found for the effect of ventilation strategy (P = 0.11). There were no significant differences in the incidence of pulmonary hemorrhage between the groups; however, NO treatment was associated with a significantly lower incidence of severe IVH and PVL compared with placebo (RR 0.53, 95% CI 0.28 to 0.98; P = 0.04). No significant between-group differences were found for pneumothorax, pulmonary interstitial emphysema, symptomatic patent ductus arteriosus, necrotizing enterocolitis, sepsis, retinopathy of prematurity, or hydrocephalus. Among survivors, the median duration of mechanical ventilation was 16 days in the NO group and 28.5 days in the placebo group (P = 0.19). The median length of hospital stay was 65 days in the NO group and 76 days in subjects receiving placebo (P = 0.22). Schreiber and colleagues concluded that early initiation of low-dose NO reduces CLD and mortality in these subjects and may also reduce the risk of severe IVH and PVL, two complications commonly associated with prematurity. Further studies adequate to detect significant interactions are recommended to reassess the effect of IMV compared with HFOV on NO treatment in this population.

[0533] Franco-Belgian collaboration on NO trial

[0534] 1999 French-Belgian collaboration NO trial group

[0535] Appendix 1

[0536] Data review and bibliography

[0537] Use in premature neonates

[0538] The Franco-Belgian Collaborative NO Trial Group evaluated the efficacy of nasopharyngeal carcinoma in preterm (GA < 33 weeks) and near-term (GA < 33 weeks) neonatal infants with severe neonatal respiratory failure (RF) and persistent hypoxemia despite mechanical ventilation and surfactant therapy. > A randomized, controlled, multicenter study was conducted to compare the effects of NO with conventional or HFOV therapy in neonates (<7 days of age) aged 33 weeks (≥33 weeks). 19Preterm infants with an OI between 12.5 and 30 were included in this study (n=85). Subjects were randomized to 10 ppm NO (n=40) or ventilation therapy (conventional mandatory or high-frequency oscillation) without NO (n=45). Subjects were also divided into three groups (RDS; idiopathic PPHN; or MAS) based on the type of lung disease, gestational age, and clinical examination. Subjects were excluded if the OI was above the upper limit requiring NO (according to the recommendations of the French Drug Agency) or if they had fatal congenital anomalies, hypoplastic left heart, cyanotic heart disease, congenital diaphragmatic hernia or other pulmonary hypoplasia, refractory septic shock, neurological abnormalities secondary to birth asphyxia, ICH, or severe left-to-right shunt PDA. Baseline arterial blood gases and ventilation / oxygenation parameters were taken and treatment was started. Measurements were repeated at 30 minutes and again after 1, 2, 6, 12, and 24 hours of treatment. Methemoglobin was measured at the 4-hour time point and every day thereafter. If the OI reached an upper limit based on GA, neonates in the control group were administered 20 ppm NO, and in the NO group exogenous surfactant and / or a switch in ventilation type (as recommended by the French Drug Agency) was performed. The primary endpoint was the reduction in OI at 2 hours. Secondary endpoints included the duration of mechanical ventilation, oxygen use, and time in the neonatal intensive care unit, as well as the incidence of CLD, ICH, PVL, and death.

[0539] The NO group had a greater reduction in OI compared with the control group (median -5.4 vs -3.6); however, this difference did not reach statistical significance (P = 0.11). No significant differences were observed between preterm NO and control subjects in survival without neurological complications (NO, 40%; control, 38%); with ICH and PVL (NO, 32%; control, 27%); or death (NO, 27%, control, 35%). Preterm neonates receiving NO spent fewer days on mechanical ventilation (12 vs 16 days), supplemental oxygen (14 vs 23 days), and in the neonatal intensive care unit (26 vs 33 days); however, none of these differences were statistically significant (P ≥ 0.29). Trial limitations reported by the authors included: 1) substantial differences in ventilator strategy, extubation, and supplemental oxygenation criteria by trial site; 2) higher baseline OI in the NO group indicating greater illness severity; 3) lack of blinding; 4) crossover from placebo to NO for ethical reasons; and 5) lower-than-expected preterm enrollment. The authors concluded that even though early, low-dose NO shortened the duration of ventilation and length of stay in the near-term neonatal intensive care unit in near-term neonates, it was not significantly beneficial in the preterm group of this study.

[0540]

[0541]

[0542]

[0543]

[0544]

[0545]

[0546]

[0547]

[0548]

[0549]

[0550]

[0551]

[0552]

[0553]

[0554]

[0555]

[0556]

[0557]

[0558]

[0559]

[0560]

[0561]

[0562] References

[0563] 1.Hamilton BE, Martin JA, Ventura SJ. Births: Preliminary Data for 2009. http: / / www.cdc.gov / nchs / data / nvsr / nbsr59 / nvsr59 03.pdf .Updated2010.Accessed August 17, 2011.

[0564] 2.Mercier JC,Olivier P,Loron G,Fontaine R,Maury L,Baud O.Inhalednitric oxide to prevent bronchopulmonary dysplasia in preterm neonates.SerninFetal Neonatal Med.2009;14(1):28-34.

[0565] 3.Bhatt AJ,Pryhuber GS,Huyck H,Watkins RH,Metlay LA,ManiscalcoWM.Disrupted pulmonaryvasculature and decreased vascular endothelial growthfactor,Flt-1,and TIE-2in human infants dying withbronchopulmonarydyspllasia.Am J Respir Crit Care Med.2001;164(10):1971-1980.

[0566] 4.Balasubramaniam V,Tang JR,Maxey A,Plopper CG,Abman SH.Mild hypoxiaimpairs alveolarization in the endothelial nitric oxide synthase-deficientmouse.Am J Physiol Lung Cell Mol Physiol.2003;284(6):L964-L971.

[0567] 5.Lin YJ,Markham NE,Balasubramaniam V,et al.Inhaled nitric oxideenhances distal lung growth after exposure to hyperoxia in neonatalrats.Pediatr Res.2005;58(1):22-29.

[0568] 6.Tang JR,Markham NE,Lin Y J,et al.Inhaled nitric oxide attenuatespulmonary hypertension and improves lung growth in infant rats after neonataltreatment with a VEGF receptor inhibitor.Am J Physiol Lung Cell MolPhysiol.2004;287(2):L344-L351.

[0569] 7.McCurnin DC,Pierce RA,Chang LY,et al.Inhaled NO improves earlypulmonary function and modifies lung growth and elastin deposition in ababoon model of neonatal chronic lung disease.Am J Physiol Lung Cell MolPhysiol.2005;288(3):L450-L459.

[0570] 8.Schreiber MD,Gin-Mestan K,Marks JD,Huo D,Lee G,Srisuparp P.Inhalednitric oxide in premature infants with the respiratory distress syndrome.NEngl J Med.2003;349(22):2099-2107.

[0571] 9.Van Meurs KP,Rhine WD,Asselin JM,Durand DJ.Response of prematureinfants with severe respiratory failure to inhaled nitric oxide.Preemie NOCollaborative Group.Pediatr Pulrnonol.1997;24(5):319-323.

[0572] 10.Van Meurs KP,Hintz SR,Ehrenkranz RA,et al.Inhaled nitric oxide ininfants>1500g and<34 weeks gestation with severe respiratory failure.JPerinatol.2007;27(6):347-352.

[0573] 11.Van Meurs KP,Wright LL,Ehrenkranz RA,et al.Inhaled nitric oxidefor premature infants with severe respiratory failure.N Engl J Med.2005;353(1):13-22.

[0574] 12.Kinsella JP,Walsh WF,Bose CL,et al.Inhaled nitric oxide inpremature neonates with severe hypoxaemic respiratory failure:a randomisedcontrolled trial.Lancet.1999;354(9184):1061-1065.

[0575] 13.Ballard RA,Truog WE,Cnaan A,et al.Inhaled nitric oxide inpreterminfants undergoing mechanical ventilation.N Engl J Med.2006;355(4):343-353.

[0576] 14.Ballard RA.Inhaled nitric oxide in preterminfants--correction.NEngl J Med.2007;357(14):1444-1445.

[0577] 15.Mercier JC,Hummler H,Durrmeyer X,et al.Inhaled nitric oxide forprevention of bronchopulmonary dysplasia in premature babies(EUNO):arandomised controlled trial.Lancet.2010;376(9738):346-354.

[0578] 16.Kinsella JP,Cutter GR,Walsh WF,et al.Early inhaled nitric oxidetherapy in premature newborns with respiratory failure.N Engl J Med.2006;355(4):1061-1065

[0579] 17.Field D,Elbourne D,Truesdale A,et al.Neonatal Ventilation WithInhaled Nitric Oxide Versus Ventilatory Support Without Inhaled Nitric Oxidefor Preterm Infants With Severe Respiratory Failure:the INNOVO multicentrerandomised controlled trial(ISRCTN 17821339).Pediatrics.2005;115(4):926-936.

[0580] 18.Hascoet JM,Fresson J,Claris O,et al.The safety and efficacy ofnitric oxide therapy in premature infants.J Pediatr.2005;146(3):318-323.

[0581] 19.Mercier JC,The Franco-Belgium Collaborative NO,Trial Group.Earlycompared with delayed inhaled nitric oxide in moderately hypoxaemic neonateswith respiratory failure:a randomised coontro1led trial.Lancet.1999;354(9184):1066-1071.

[0582] 20.Donohue PK,Gilmore MM,Cristofalo E,et al.Inhaled Nitric Oxide inPreterm Infants:A Systematic Review.Pediatrics.2011.

[0583] 21.Askie LM,Ballard RA,Cutter GR,et al.Inhaled Nitric Oxide inPreterm Infants:An Individual-Patient Data Meta-analysis of RandomizedTrials.Pediatrics.2011.

[0584] 22.Barrington K J,Finer N.Inhaled nitric oxide for respiratoryfailure in preterm infants.Cochrane Database Syst Rev.2010;12:CD000509.

[0585] 23.Hoehn T,Krause MF,Buhrer C.Meta-analysis of inhaled nitric oxidein premature infants:an update.Klin Padiatr.2006;218(2):57-61.

[0586] 24.Hoehn T,Krause MF,Buhrer C.Inhaled nitric oxide in prematureinfants--a meta-analysis.J Perinat Med.2000;28(1):7-13.

[0587] 25.Srisuparp P,Heitschmidt M,Schreiber MD.Inhaled nitric oxidetherapy in premature infants with mild to moderate respiratory distresssyndrome.J Med Assoc Thai.2002;85 Suppl 2:S469-S478.

[0588] 26.Watson RS,Clermont G,Kinsella JP,et al.Clinical and economiceffects of iNO in premature newborns with respiratory failure at 1year.Pediatrics.2009;124(5):1333-1343.

[0589] 27.Hibbs AM,Walsh-Sukys MC,Martin R J,et al.One-year respiratoryoutcomes of preterm infants enrolled in the Nitric Oxide(to prevent)ChronicLung Disease trial.J Pediatr.2008;153(4):525-529.

[0590] 28.Hoo AF,Beardsmore CS,Castle RA,et al.Respiratory function duringinfancy in survivors of the INNOVO trial.PediatrPulmonol.2009;44(2):155-161.

[0591] 29.Walsh-Sukys MC,Hibbs AM,Martin CR,et al.Two-yearNeurodevelopmental Outcomes of Ventilated Preterm Infants Treated withInhaled Nitric Oxide.J Pediatr.2010;156(4):556-561.

[0592] 30.Keller RL,Walsh-Sukys MC,Vittinghoff E,Palermo L,Ballard PL,Ballard RA..Response to Inhaled Nitric Oxide(iNO)and NeurodevelopmentalImpairment(NDI)in NO CLD.Baltimore,MD:2009.

[0593] 31.Kinsella JP,Cutter GR,Walsh WF,et al..Outcomes of PrematureInfants Enrolled in the Early Inhaled Nitric Oxide for the Prevention ofChronic Lung Disease Trial,Baltimore,MD:2009.

[0594] 32.Hintz SR,Van Meurs KP,Perritt R,et al.Neurodevelopmental outcomesof premature infants with severe respiratory failure enrolled in a randomizedcontrolled trial of inhaled nitric oxide.J Pediatr.2007;151(1):16-22.

[0595] 33.Mestan KK,Marks JD,Hecox K,Huo D,Schreiber MD,Neurodevelopmentaloutcomes of premature infants treated with inhaled nitric oxide.N Engl JMed.2005;353(1):23-32.

[0596] 34.Durrmeyer X,Hummler H,Sanchez-Luna M,et al.Two-Year Outcomes of aRandomized Controlled Trial of Inhaled Nitric Oxide in PrematureInfants.Pediatrics.2013.

[0597] 35.Huddy CL,Bennett CC,Hardy P,et al.The INNOVO multicentrerandomised controlled trial:Neonatal ventilation with Inhaled Nitric Oxideversus Ventilatory support without nitric oxide for severe respiratoryfailure in preterm infants:follow up at 4-5 years(ISRCTN 17821339).Arch DisChild FetalNeonatal Ed.2008.

[0598] 36.Patrianakos-Hoobler Al,Marks JD,Msall ME,Huo D,Schreiber MD.Safetyand efficacy of inhaled nitric oxide treatment for premature infants withrespiratory distress syndrome:follow-up evaluation at early school age.ActaPaediatr.2011;100(4):524-528.

[0599] 37.Hamon I,Gaga S,Espagne S,Merdariu D,Debruille C,HascoetJM..Clinical Outcome at 7 Years of Age in Former Premature Infants Treated atBirth with Inhaled Nitric Oxide(iNO).Baltimore,MD:2009.

[0600] 38.Hamon I,Deforge H,Espagne S,Gaga S,Selton D,HascoetJM..Neurodevelopmental and Cognitive Outcomes at School Age of PrematureInfants Treated at Birth with Inhaled Nitric Oxide(iNO).Baltimore,MD:2009.

[0601] 39.Hascoet JM,Marchal F,Schweitzer C,Tankeu S,Hamon I..RespiratoryOutcome at 7 Years of Age in Former Sick Premature Infants Treated withInhaled Nitric Oxide(iNO)at Birth.Baltimore,MD:2009.

[0602] 40.Ballard PL,Truog WE,Merrill JD,et al.Plasma biomarkers ofoxidative stress:relationship to lung disease and inhaled nitric oxidetherapy in premature infants.Pediatrics.2008;121(3):555-561.

[0603] 41.Cooper S,Marks JD,Meisel M,White MK,Huo D,Schreiber MD.Birthweightdistribution of severe IVH / PVL and death in premature infants treated withinhaled nitric oxide.Pediatr Res.2011;70(4):AbsE-PAS20113835.358433.

[0604] 42.Ambalavanan N,Van Meurs KP,Perritt R,et al.Predictors of death orbronchopulmonary dysplasia in preterm infants with respiratoryfailure.Journal of Perinatology:Official Journal of the California PerinatalAssociation.2008;28(6):420-426.

[0605] 43.Hintz S,Van Meurs KP,The NICHD Neonatal RN..Reliability andAccuracy of Cranial Ultrasound in the NICHD Randomized Controlled Trial ofInhaled Nitrix Oxide for Premature Infants with Severe RespiratoryFailure.San Francisco,CA:2006.

[0606] 44.White M,Marks JD,Schreiber SA,Huo D,Msall ME and Schreiber MD.NoEffect of Inhaled Nitric Oxide on IVH Extension in Premature Infants withModerate RDS.05 / 02,Poster E-PAS20102849.278.

[0607] 45.Kaplan H,Lorch SA,Luan X,et al..Role of Inhaled Nitric Oxide inEvolution of Brain Lesions in the Premature Infant.San Francisco,CA:2006.

[0608] 46.Desandes R,Desandes E,Droulle P,Didier F,Longrois D,HascoetJM.Inhaled nitric oxide improves oxygenation in very premature infants withlow pulmonary blood flow.Acta Paediatr.2004;93(1):66-69.

[0609] 47.Truog WE,Ballard PL,Norberg M,et al.Inflammatory markers andmediators in trachealfluid of premature infants treated with inhaled nitricoxide.Pediatrics.2007;119(4):670-678.

[0610] 48.Izhar FM,Rumilla K,Kim Y,Hershenson MB,Schreiber MD..InhaledNitric Oxide Prevents the Increase in Tracheal Aspirate IL-8 Concentrationsin Premature Newborn Infants with Respiratory Distress Syndrome.Baltimore,MD:2001.

[0611] 49.Posencheg MA,Gow A J,Truog WE,et al.Inhaled nitric oxide inpremature infants:effect on tracheal aspirate and plasma nitric oxidemetabolites.J Perinatol.2010;30(4):275-280.

[0612] 50.Ballard PL,Keller RL,Harmon C and Ballard RA.Urinary Nitric OxideMetabolites in Preterm Infants with Lung Disease.05 / 01,Poster E-PAS20101464.117.

[0613] 51.Keller RL,Vittinghoff E,Palermo L,Ballard RA,Ballard PL,TruogW..Response to Inhaled Nitric Oxide (iNO):Further analysis of the NO CLDTrial.Balttimore,MD:2009.

[0614] 52.Ahluwalia J,Tooley J,Cheema l,et al.A dose response study ofinhaled nitric oxide in hypoxic respiratory failure in preterm infants.EarlyHum Dev.2006;82(7):477-483.

[0615] 53.Sokol GM,Van Meurs KP,The NICHD Neonatal RN..Does Inhaled NitricOxide(iNO)Exhibit Dose Related Toxicity in the Premature Infant with SevereRespiratory Failure?San Francisco,CA:2006.

[0616] 54.Chock VY,Van Meurs KP,Hintz SR,et al.Inhaled Nitric Oxide forPreterm Premature Rupture of Membranes,Oligohydramnios,and PulmonaryHypoplasia.Am J Perinatol.2009;26(4):317-322.

[0617] 55.Di Fiore JM,Hibbs AM,Zadell AE,et al.The effect of inhaled nitricoxide on pulmonary function in preterm infants.J Perinatol.2007;27(12):766-771.

[0618] 56.Izhar FM,Rumilla K,Borg M J,Kim Y,Hershenson MB,SchreiberMD..Pulmonary Safety of Inhaled Nitric Oxide in Premature Newborn Infantswith Respiratory Distress.Boston,MA:2000.

[0619] 57.Truffert P,Llado-Paris J,Mercier JC,Dehan M,Breart G.Early inhalednitric oxide in moderatelyhypoxemic preterm and term newborns with RDS:theRDS subgroup analysis of the Franco-Belgian iNO Randomized Trial.Eur JPediatr.2003;162(9):646-647.

[0620] 58.Gordon PV,Aschner JL,The Preemie iNO Subcommittee on Behalf of theNICHD Neonatal,Research Network..Can Inhaled Nitric Oxide(iNO)Alter theNatural History of Spontaneous Intestinal Perforations (SIP)in the ELBWInfant?:A Post Hoc Analysis of the NICHD Preemie iNO Study.San Francisco,CA:.

[0621] 59.Ballard PL,Merrill JD,Truog WE,et al.Surfactant function andcomposition in premature infants treated with inhaled nitricoxide.Pediatrics.2007;120(2):346-353.

[0622] 60.Aikio O,Metsola J,Vuolteenaho R,Perhomaa M,Hallman M.TransientDefect in Nitric Oxide Generationafter Rupture of Fetal Membranes andResponsiveness to Inhaled Nitric Oxide in Very Preterm Infants with HypoxicRespiratory Failure.J Pediatr.2012.

[0623] 61.Sharma S,Palafoutas J and Ramasethu J.Inhaled nitric oxide(iNO)inmanagement of pulmonaryhypertension(PPHN)in preterm infants.Presented at:Pediatric Academic Societies and Asian Society for Pediatric Research AnnualMeeting,April 30 to May 3,2011,Denver,CO.Abstract E-PAS2011809.Accessed at: http: / / www.abstracts2view.com / pes / view.php?nu=PAS11L1 1791 .

[0624] 62.O′Donnell DC,Franta J and Miletin J.The use of Inhaled NitricOxide in Premature Infants with Premature Rupture of Membranes:A CaseSeries.Presented at:Neonatology,2010,E-PAS2010563.

[0625] 63.Dewhurst C,Ibrahim H,Gothberg S,Jonsson B,Subhedar N.Use ofinhaled nitric oxide in the new born period:results from the European inhalednitric oxide registry.Acta Paediatr.2010.

[0626] 64.Hopper AO,Ninnis JR,Mulla N,Peverini R,Terry M and DemingD.Persistent Pulmonary Hypertension in Very Low Birth Weight Infants:Role forInhaled Nitric Oxide?05 / 09,Abstract 3857.86.

[0627] 65.Kumar VH,Hutchison AA,Lakshminrusimha S,Morin FC,III,Wynn RJ,RyanRM.Characteristics of pulmonary hypertension in preterm neonates.JPerinatol.2007;27(4):214-219.

[0628] 66.Su PH,Chen JY.Inhaled nitric oxide in the management of preterminfants with severe respiratory failure.J Perinatol.2008;28(2):112-116.

[0629] 67.Khemani E,McEIhinney DB,Rhein L,et al.Pulmonary arteryhypertension in formerly premature infants with bronchopulmonary dysplasia:clinical features and outcomes in the surfactant era.Pediatrics.2007;120(6):1260-1269.

[0630] 68.Tanaka Y,Hayashi T,Kitajima H,Sumi K,Fujimura M.Inhaled nitricoxide therapy decreases the risk of cerebral palsy in preterm infants withpersistent pulmonary hypertension of the newborn.Pediatrics.2007;119(6):1159-1164.

[0631] 69.Dani C,Bertini G,Pezzati M,Filippi L,Cecchi A,RubaltelliFF.Inhaled nitric oxide in very preterm infants with severe respiratorydistress syndrome.Acta Paediatr.2006;95(9):1116-1123.

[0632] 70.Dani C,Bertini G.Inhaled nitric oxide for the treatment of preterminfants with respiratory distress syndrome.Neonatology.2008;94(2):87-95.

[0633] 71.Lindwall R,Blennow M,Svensson M,et al.A pilot study of inhalednitric oxide in preterm infants treated with nasal continuous positive airwaypressure for respiratory distress syndrome.Intensive Care Med.2005;31(7):959-964.

[0634] 72.Uga N,Ishii T,Kawase Y,Arai H,Tada H.Nitric oxide inhalationtherapy in very Iow-birthweight infants with hypoplastic 1ung due tooligohydramnios.Pediatr Int.2004;46(1):10-14.

[0635] 73.Athavale K,Claure N,D′Ugard C,Everett R,Swaminathan S,BancalariE.Acute effects of inhaled nitric oxide on pulmonary and cardiac function inpreterm infants with evolving bronchopulmonary dysplasia.J Perinatol.2004;24(12):769-774.

[0636] 74.Aikio O,Saarela T,Pokela ML,Hallman M.Nitric oxide treatment andacute pulmonary inflammatory response in very premature infants withintractable respiratory failure shortly after birth.Acta Paediatr.2003;92(1):65-69.

[0637] 75.Clark PL,Ekekezie II,Kaftan HA,Castor CA,Truog WE.Safety andefficacy of nitric oxide in chronic lung disease.Arch Dis Child FetalNeonatal Ed.2002;86(1):F41-F45.

[0638] 76.Truog WE,Pallotto E,Clark P,et al.Interaction of endogenousendothelin-1 and inhaled nitric oxide in term and preterm infants.Clin Sci(Lond).2002;103 Suppl48:294S-297S.

[0639] 77.Du LZ,Shi LP,Zhou BH,et al.Inhaled nitric oxide in preterm andterm neonates with hypoxemic respiratory failure and persistent pulmonaryhypertension.Acta Pharmacol Sin.2002;23:69-73.

[0640] 78.Banks BA,Seri I,Ischiropoulos H,Merrill J,Rychik J,BallardRA.Changes in oxygenation with inhaled nitric oxide in severebronchopulmonary dysplasia.Pediatrics.1999;103(3):610-618.

[0641] 79.Cheung PY,Peliowski A,Robertson CM.The outcome of very low birthweight neonates(< / =1500g)rescued by inhaled nitric oxide:ne urodevelopmentin early childhood.J Pediatr.1998;133(6):735-739.

[0642] 80.Laubscher B,Greenough A,Kavvadia V,Devane SP.Response to nitricoxide in term and preterm infants.Eur J Pediatr.1997;156(8):639-642.

[0643] 81.Skimming JW,Bender KA,Hutchison AA,Drummond WH.Nitric oxideinhalation in infants with respiratory distress syndrome.J Pediatr.1997;130(2):225-230.

[0644] 82.Subhedar NV,Ryan SW,Shaw NJ.Open randomised controlled trial ofinhaled nitric oxide and early dexamethasone in high risk preterminfants.Arch Dis Child Fetal Neonatal Ed.1997;77(3):F185-F190.

[0645] 83.Peliowski A,Finer NN,Etches PC,Tierney AJ,Ryan CA.Inhaled nitricoxide for premature infants after prolonged rupture of the membranes.JPediatr.1995;126(3):450-453.

[0646] 84,Bennett AJ,Shaw NJ,Gregg JE,Subhedar NV.Neurodevelopmental outcomein high-risk preterm infants treated with inhaled nitric oxide.ActaPaediatr.2001;90(5):573-576.

[0647] 85,Subhedar NV,Shaw NJ,Changes in oxygenation and pulmonaryhaemodynamics in preterm infants treated with inhaled nitric oxide.Arch DisChild Fetal Neonatal Ed.1997;77(3):F191-F197.

[0648] 86.Cole FS,Alleyne C,Barks JD,et al.NIH Consensus DevelopmentConference Statement:Inhaled Nitric-Oxide Therapy for PrematureInfants.Pediatrics.2011.

[0649] 87.Barrington KJ,Finer NN.Inhaled nitric oxide for respiratoryfailure in preterm infants.Cochrane Database Syst Rev.2009(1):CD000509.

[0650] 88.Ballard PL,Gonzales LW,Godinez RI,et al.Surfactant composition andfunction in a primate model of infant chronic lung disease:effects of inhalednitric oxide.Pediatr Res.2006;59(1):157-162.

[0651] 89.Gadhia MM,Cutter GR,Abman SH,Kinsella JP.Effects of Early InhaledNitric Oxide Therapy and Vitamin A Supplementation on the Risk forBronchopulmonary Dysplasia in Premature Newborns with Respiratory Failure.JPediatr.2013.

[0652] 90.Hamon I,Fresson J,Nicolas MB,Buchweiller MC,Franck P,HascoetJM.Early inhaled nitric oxide improves oxidative balance in very preterminfants.Pediatr Res.2005;57(5):637-643.

[0653] 91.Van Meurs KP,Stevenson DK,Ehrenkranz RA,et al..Inhaled NitricOxide for Preterm Infants with Severe Respiratory Failure.San Francisco,CA:2004.

[0654] 92.Van Meurs KP,Benitz W,Hintz S,Bender RH,Poole K,for the NICHDNeonatal,Research Network..Does Oxygenation Index Correlate with Outcome inPremature Infants with Respiratory Failure?Washington,DC:2005.

[0655] 93.Finer NN.Inhaled nitric oxide for preterm infants:a therapy insearch of an indication?The search continues.J Pediatr.2005;146(3):301-303.

[0656] 94.Kumar A,Zarychanski R,Pinto R,et al.Critically III Patients With2009 Influenza A(H1N1)Infection in Canada.JAMA.2009;302(17):1872-1879.

[0657] 95.Davidson D,Barefield ES,Kattwinkel J,et al.Inhaled nitric oxidefor the early treatment of persistent pulmonary hypertension of the termnewborn:a randomized,double-masked,placebo-controlled,dose-response,multicenter study.The I-NO / PPHN Study Group.Pediatrics.1998;101(3):325-334.

[0658] 96.Yadav M,Emmerson AJ.Inhaled nitric oxide in prematureneonates.Lancet.1999:354(9196):2162-2163.

[0659] 97.Konduri GG,Vohr B,Robertson C,et al.Eariy inhaled nitric oxidetherapy for term and near-term newborn infants with hypoxic respiratoryfailure:neurodevelopmental follow-up.J Pediatr.2007;150(3):235-40,240.

Claims

1. A method of optimizing settings of a left ventricular assist device (LVAD), the method comprising: administering inhaled nitric oxide to patients with LVADs; performing an echocardiogram on said patient during administration of inhaled nitric oxide; and during the echocardiogram and during the administration of inhaled nitric oxide, adjusting or setting one or more parameters of the LVAD to optimize cardiac output, Adjusting or setting one or more parameters of the LVAD includes one or more of: (i) determining a low pump speed setting for the LVAD based on a minimum pump speed required for the patient's aortic valve to open with each heartbeat, or (ii) determining a high pump speed setting for the LVAD based on a pump speed at which the patient's heart septum flattens.

2. The method of claim 1, wherein the inhaled nitric oxide is administered at a concentration of 5 to 80 ppm for at least 10 minutes.

3. A method of reducing the risk of right ventricular failure during use of a left ventricular assist device (LVAD), the method comprising: confirming that the LVAD is functional prior to administering inhaled nitric oxide; Administering inhaled nitric oxide to patients with LVADs for at least 12 hours per day for at least 20 days to reduce the risk of right ventricular failure, wherein said inhaled nitric oxide is not initially administered after the patient is weaned from cardiopulmonary bypass (CPB).

4. The method of claim 3, wherein the inhaled nitric oxide is administered at a concentration of 5 to 80 ppm or at a dose of 25 to 150 μg / kg IBW / h.

5. The method of claim 3, further comprising monitoring one or more output parameters of the LVAD and / or one or more hemodynamic parameters of the patient, comparing the one or more output parameters and / or the one or more hemodynamic parameters with a predetermined range, and adjusting the dose of inhaled nitric oxide if the one or more output parameters and / or the one or more hemodynamic parameters are outside of the predetermined range.

6. The method according to claim 5, further comprising: If the one or more output parameters and / or the one or more hemodynamic parameters are outside of the predetermined range, an alert is provided.

7. A method of monitoring the left ventricle of a patient having a left ventricular assist device (LVAD), the method comprising: reducing the pump speed of the LVAD or shutting down the LVAD; measuring one or more pulmonary hemodynamic parameters of the patient to obtain a first pulmonary hemodynamic value; preloading the left ventricle by administering inhaled nitric oxide to the patient; and One or more pulmonary hemodynamic parameters of the patient are measured after or during administration of inhaled nitric oxide to obtain a second pulmonary hemodynamic value.

8. The method of claim 7, wherein the pulmonary hemodynamic parameter is selected from the group consisting of left atrial pressure (LAP), pulmonary capillary wedge pressure (PCWP) and cardiac output (CO).

9. The method of claim 7, wherein the inhaled nitric oxide is administered at a concentration of 5 to 80 ppm for at least 10 minutes.

10. The method of claim 9, wherein an increase in LAP and / or PCWP from the first pulmonary hemodynamic value to the second pulmonary hemodynamic value of less than 5 mm Hg indicates that the left ventricle is improving.

11. The method of claim 10, further comprising modifying therapy if the left ventricle is improving, the modification comprising removing the LVAD from the patient.

12. The method of claim 10, wherein preloading the left ventricle comprises administering inhaled nitric oxide at a concentration of 5 to 80 ppm for a period of 5 to 30 minutes, the preloading being performed one to five times per day.

13. The method of claim 10, further comprising exercising the heart, the exercising comprising: ceasing said administration of inhaled nitric oxide; and The preloading and stopping are repeated to exercise the left ventricle of the patient's heart.